ЭМУЛЬСИИ ИЛИ МИКРОЭМУЛЬСИИ ДЛЯ ПРИМЕНЕНИЯ В ЭНДОСКОПИЧЕСКОЙ РЕЗЕКЦИИ СЛИЗИСТОЙ И/ИЛИ ЭНДОСКОПИЧЕСКОЙ ПОДСЛИЗИСТОЙ ДИССЕКЦИИ

SEPARATION OF THROMBOZYTEN FROM FULL BLOOD FOR USE AS WUNDHEILMITTEL

BIOLOGISCHES RESORBIERBARES IMPLANTATIONSMATERIAL SOWIE VERFAHREN ZUR HERSTELLUNG DESSELBEN

PROCEDURE FOR THE PRODUCTION OF A GEL OF AUTO+LIED BLOOD PANELS

ADHESIVE PREPARATION AND THEIR USE

SPRAYINGCASH BONE SUBSTITUTE CONTAINING FIBRIN OR FIBRINOGEN AS WELL AS HYDROXYL APATITE CEMENT

IMPROVED FABRIC ADHESIVE, PREPARED OUT KRYOPRÄZIPITAT

Molded implants for orthopedic applications

Soft and calcified tissue implants

Adhesive agent and use of such agent

METHOD AND MATERIAL FOR ENHANCE TISSUE-BIOMATERIAL INTEGRATION

The present invention provides a composition and method for the covalent binding of a hydrogel to an extracellular matrix (ECM). Therapeutic applications include tissue repair and delivery of drugs or cells.

METHOD OF MANUFACTURING ACELLULAR MATRIX GLUE

An acellular matrix glue and a method of making is disclosed. Specifically, an acellular matrix glue that is useful in preparing a reinforced acellular matrix for medical applications including tissue engineering and hernia repair.

COMPOSITION FOR FILLING BONE DEFECTS

The invention is directed toward a formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles: The particle size ranges from about 0.1 mm to about 1.0cm and is mixed in a hydrogel carrier containing a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 1.0 to 5.0% of the composition and a pH between 6.8-7.4 with one or more additives of a cellular material, growth factor, demineralized bone chips or mineralized bone chips.

COMPOSITIONS COMPRISING EPITHELIAL CELLS FOR THE TREATMENT AND PREVENTION OF TISSUE ADHESIONS

Compositions and methods are described for the treatment and prevention of abdominal and thoracic adhesions as well as other adhesions using a cell- sustaining and surface-separating composition that nourishes and sustains grafted or present non-keratinizing (i.e. nonepidermal) epithelial cells. The composition is preferably a suspension of viable epithelial cells in a polymerizable, absorbable composition, such as fibrin glue, that will provide separation of the organ surfaces and nourishment to seeded and grafted cells.

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, said endoscopic procedure preferably comprising the administration of said pharmaceutical composition to a human. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human.

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, preferably said endoscopic procedure comprising the administration of said pharmaceutical composition to a human with the aim of improving and facilitating the resection of the lesion by raising the area where the lesion is located. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human. The invention herein disclosed also provides a kit for use in an endoscopic procedure, said kit comprising a pharmaceutical composition in form of emulsion or microemulsion, an endoscopic injection needle, a syringe and instructions for use thereof.

MINIMALLY INVASIVE TREATMENT OF VERTEBRA (MITV) USING A CALCIUM PHOSPHATE COMBINATION BONE CEMENT

Featured are a biocompatible, injectable, self-setting, cohesive, bone-bonding and remodeling calcium phosphate composite material and its use in methods of repairing defective bone, e.g., in vertebroplasty augmentation and kyphoplasty.

COMPOSITIONS, USES, AND PREPARATION OF PLATELET LYSATES

In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method.

MEDICAL ABSORBABLE HEMOSTATIC MATERIAL FOR BONE WOUNDS AND PREPARATION METHOD THEREFOR

A medical absorbable hemostatic and wound healing promoting material for bone wounds and a preparation method therefor. The absorbable hemostatic material for bone wounds is formed of 40-95% of a base material and 5-60% of an adjuvant, based on weight percent, wherein the base material is an oligosaccharide, a polysaccharide, or a mixture of the oligosaccharide and the polysaccharide; and the adjuvant includes (1) one or more polyhydric alcohols, (2) one or more vegetable oils, and (3) one or more emulsifying agents. The method for preparing the absorbable hemostatic and wound healing promoting material for bone wounds comprises mixing a base material and an adjuvant at prescribed amounts by chemical blending or latex blending, cooling to form a solid lump, packaging, and sterilizing.

HEMOSTATIC DEVICE

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

OSTEOGENIC COMPOSITION AND IMPLANT CONTAINING SAME

An osteogenic composition is obtained from demineralized bone tissue.

OSTEOGENIC COMPOSITION AND IMPLANT CONTAINING SAME

An osteogenic composition is obtained from demineralized bone tissue.

MODIFIED OSTEOGENIC MATERIALS

A process and product comprising collagen and demineralized bone particles. The product may contain a maximum of 20 % by weight inorganic materials. The product may be densified by compression. Additional osteogenic factors, mitogens, drugs or antibiotics may be incorporated therein. Inorganic materials may be bound to the organic matrix via precoating with a calcium or hydroxyapatite binding protein, peptide or amino acid. The materials also display long lasting drug release characteristics. The subject of this invention is a process and resultant composition which increases the rate and predictability of osteoinduction by demineralized bone matrix. In particular, this invention relates to compositions of demineralized bone and calcium or other mineral salts which exhibit enhanced osteogenic potential. This invention further relates to osteogenic compositions comprising between about 60 % to 90 % demineralized bone by weight and to compositions comprising a carrier and alkaline phosphatase ...

METHODS AND COMPOSITIONS FOR PROGRAMMING AN ORGANIC MATRIX FOR REMODELING INTO A TARGET TISSUE

Methods for programming a non-immunogenic matrix for remodeling into a target tissue are disclosed. Also disclosed are compositions which can promote the growth of selected tissue types in a subject. Methods for preparing the compositions are also described. The methods and compositions are useful for treatment of tissue defects in tissues such as bone, cartilage, and muscle.

Verfahren zur Herstellung eines Blutstill- und Wundheilmittels.

Gel dressing for wound healing

BONE CEMENT CONTAINING BONE MARROW

BONE PASTE

FIBRIN-BASED BIOMATRIX

The invention involves methods and materials related to fibrin-based biomatrices.

IMPLANTS FOR ORTHOPEDIC APPLICATIONS

An implant and a method for making and using the implant are disclosed for the repair of bone defects or voids, including defects or voids in the acetabular cup. The implant shapes and compositions of this invention provide advantages not present in impaction grafts and like implants known in the art. Also disclosed is an osteogenic, cross-linked composite implant, and methods of producing the same.

AN INJECTABLE BONE MINERAL SUBSTITUTE MATERIAL

An injectable bone mineral substitute material composition comprises an inorganic bone cement powder and a biologically compatible oil. The oil is an intermixture with the cement powder at a concentration of less than 10 wt% of the total weight of the composition in order to improve the rheology of the same. In a method of intermixing a powder of an implant material and a biologically compatible oil to a composition the oil is mixed with the powder of implant material at an elevated temperature.

Novel Adhesive Materials, Manufacturing Thereof, and Applications Thereof

A novel composition-of-matter, method of manufacturing thereof, and applications thereof as an adhesive, in a wide variety of different fields, and in particular, in the health care fields of medicine, dentistry, and veterinary science, for use by health care providers, such as medical, dental, and veterinary, surgeons, in procedures for reattaching or repairing body parts or components thereof, such as tissue, of (human or animal) subjects, especially under wet conditions, for example, involving adhesion of wet surfaces. The composition is comprised of a cross-linked form of a water miscible polymer, and at least one phloroglucinol type compound selected from the group consisting of: phloroglucinol, a derivative of phloroglucinol, and a polymer synthetically prepared from phloroglucinol or a derivative of phloroglucinol. An exemplary water miscible polymer is a naturally existing, or synthetically prepared, salt form of the carbohydrate alginic acid, such as sodium alginate, or alginic ...

Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use

A composition comprising a collagen protein and demineralized bone matrix is described wherein the composition is chemically cross-linked with a carbodiimide such as N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC). The crosslinking reaction can be conducted in the presence of N-hydroxysuccinimide (NHS). The collagen can be in a porous matrix or scaffolding. The DBM can be in the form of particles dispersed in the collagen. A method of making the composition is also described wherein a collagen slurry is cast into the desired shape, freeze dried to form a porous scaffolding and infitrated with a solution comprising the cross-linking agent. The composition can be used as an implant for tissue (e.g., soft tissue or bone) engineering.

ADHESIVE COMPLEX COACERVATES PRODUCED FROM ELECTROSTATICALLY ASSOCIATED BLOCK COPOLYMERS AND METHODS FOR MAKING AND USING THE SAME

MODIFIED GRAFTS

Grafts modified with one or more bioactive substances are provided, as well as methods to make and use them. More particularly, the present invention relates to modified grafts having characteristics which facilitate tissue generation, repair, and reconstruction, and which are modified with bioactive substances, such as one or more proteins and minerals, whose bioactivity further facilitates tissue generation, repair, and reconstruction. Methods for producing the modified grafts include depositing the one or more bioactive substances onto, into, or both, a substrate material. In certain exemplary embodiments, the substrate material comprises a tissue derived matrix produced by processing one or more tissue samples, and the bioactive materials are precipitated from a solution produced during that processing, such as during demineralization of bone tissue samples or delipidation of adipose tissue samples, wherein the one or more bioactive substances comprise proteins and minerals endogenous ...

МЕДИЦИНСКИЙ АБСОРБИРУЕМЫЙ ГЕМОСТАТИЧЕСКИЙ МАТЕРИАЛ ДЛЯ КОСТНЫХ РАН И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Группа изобретений относится к медицине. Описан медицинский абсорбируемый гемостатический и ранозаживляющий материал для костных ран и способ его получения. Абсорбируемый гемостатический материал для костных ран содержит 40-95% основного материала и 5-60% вспомогательного средства на основе процентного содержания по весу, где основной материал представляет собой олигосахарид, полисахарид или смесь олигосахарида и полисахарида, а вспомогательное средство включает (1) один или несколько многоатомных спиртов, (2) одно или несколько растительных масел и (3) одно или несколько эмульгирующих веществ. Способ получения абсорбируемого гемостатического и ранозаживляющего материала для костных ран включает этапы, на которых смешивают основной материал и вспомогательное средство в заданных количествах путем химического смешивания и приготовления смеси в стадии латекса, охлаждают с образованием цельного куска, упаковывают и стерилизуют. Материал полностью поддается разложению в организме и способствует ...

КОМБИНАЦИЯ КРОВИ И КЕРАМИЧЕСКИХ ЧАСТИЦ ДВУХФАЗНЫХ ФОСФАТОВ КАЛЬЦИЯ

... 1. Способ получения биоматериала, включающий по меньшей мере следующие стадии: ! (i) смешивание двухфазного фосфата кальция, или BCP, в виде гранул размером от 40 до 500 мкм с кровью или аспиратом костного мозга в соотношении от 10 до 90 мас.% BCP от объема крови или костного мозга в г/мл; ! (ii) прибавление к смеси, полученной на стадии (i), по меньшей мере одного коагулянта в количестве, достаточном для вызывания коагуляции крови или костного мозга; ! (iii) перемешивание в условиях, благоприятствующих гомогенизации BCP, в течение времени прохождения коагуляции. ! 2. Способ по п.1, в котором коагулянт на основе кальция выбран из биологически совместимых солей кальция и предпочтительно из CaCl2. ! 3. Способ по п.1, в котором кровь предварительно отбирают у донора, совместимого с реципиентом, которому предназначен биоматериал. ! 4. Способ по п.1, в котором кровь предварительно отбирают у реципиента, которому предназначен биоматериал. ! 5. Способ по п.1, в котором смесь, содержащую BCP, кровь ...

KLEBSTOFFEZUBEREITUNG UND DEREN VERWENDUNG

Knochenbildende Zusammensetzung und ein diese enthaltendes Implantat

ARZNEIMITTEL ZUR FÖRDERUNG DER WUNDHEILUNG

BIOLOGISCHES RESORBIERBARES IMPLANTATIONSMATERIAL SOWIE VERFAHREN ZUR HERSTELLUNG DESSELBEN

WUNDVERSCHLUSSSYSTEM AND PROCEDURE

PROCEDURE FOR THE PRODUCTION OF A BONE CEMENT

SURGICAL ADHESIVE MATERIAL.

INJIEZIERBARES BONE SUBSTITUTE CONTAINING BONE CEMENT AND OIL

Methods of repairing longitudinal bone defects

Modified osteogenic materials

Fibrin-cell suspension for construction of new tissue

A prolamine-plant polar lipid composition, its method of preparation and applications thereof

Hemostatic device

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof

The invention relates to a pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from the group comprising Pinctadines, notably Pinctada maxima, margaritifera, and Tridacnes, notably Tridacna gigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, in pulverulent form, with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation; it also relates to the method of preparation thereof and to the uses thereof.

Compositions and methods for adhesion to surfaces

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection.

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, preferably said endoscopic procedure comprising the administration of said pharmaceutical composition to a human with the aim of improving and facilitating the resection of the lesion by raising the area where the lesion is located. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human. The invention herein disclosed also provides a kit for use in an endoscopic procedure, said kit comprising a pharmaceutical composition in form of emulsion or microemulsion, an endoscopic injection needle, a syringe and instructions for use thereof.

Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection.

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, preferably said endoscopic procedure comprising the administration of said pharmaceutical composition to a human with the aim of improving and facilitating the resection of the lesion by raising the area where the lesion is located. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human. The invention herein disclosed also provides a kit for use in an endoscopic procedure, said kit comprising a pharmaceutical composition in form of emulsion or microemulsion, an endoscopic injection needle, a syringe and instructions for use thereof.

SEMI-SYNTHETIC POWDER MATERIAL, OBTAINED BY MODIFYING THE COMPOSITION OF A NATURAL MARINE BIOMATERIAL, METHOD FOR PRODUCING SAME, AND APPLICATIONS THEREOF

L'invention porte sur un matériau semi-synthétique, pulvérulent, issu d'un biomatériau naturel marin qui est la couche aragonitique interne de la coquille de mollusques bivalves choisis dans le groupe comprenant des Pinctadines, notamment Pinctada maxima, margaritifera, et des Tridacnes, notamment Tridacna gigas,maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, sous forme pulvérulente, additionné de bio-polymères insolubles et solubles et de carbonate de calcium transformé par carbonatation; elle porte également sur son procédé de préparation et sur ses utilisations.

TISSUE GLUE PREPARED BY USING CRYOPRECIPITATE

A tissue glue is described comprising a component A which comprises a cryoprecipitate of whole blood and high an amount of a protease inhibitor corresponding to 3,000 to 5,000 KIU/ml units of aprotinin, and a component B comprising a proteolytic enzyme being capable of cleaving specifically fibrinogen present in component A and causing the formation of a fibrine polymer. In another embodiment an improved tissue glue is described comprising a component A which comprises a cryoprecipitate of whole blood, and a component B comprising a proteolytic enzyme obtainable from snake venom which enzyme is capable of cleaving specifically fibrinogen present in component A and causing the formation of a fibrine polymer.

COLLAGEN MEDICAL ADHESIVE AND ITS USES

An adhesive composition suited for surgical applications which consists essentially of an aqueous solution of natural collagen which has a melt index temperature within the range of 35.degree.C to 45.degree.C.

A preparation method and application of cloth-like hemostatic material

MATERIALS AND METHODS FOR TREATING AND MANAGING WOUNDS AND THE EFFECTS OF TRAUMA

Disclosed herein are materials and methods suitable for treating traumatic injury sites resulting from wounds, surgery or other tissue disruption. Traumatic injury sites can be treated by contacting a surface of a traumatic injury at or adjacent or in the vicinity of an area of injury or damage with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the traumatic injury site. A composition comprising a biocompatible matrix and cells engrafted therein or thereon can be used to treat the traumatic injury site. The composition can be a flexible planar material or a flowable composition.

Osteogenic composition and implant containing same

An osteogenic composition is obtained from demineralized bone tissue.

Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection.

Autologous fibrin sealant and method for making the same

The present relates to an autologous bioadhesive sealant composition or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment, the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the platelet rich plasma to form the bioadhesive sealant of the present invention.

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A pharmaceutical composition comprising:(a) at least one poloxamer selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, or a mixture thereof; and(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C. in vitro,wherein the pharmaceutical composition is for use in submucosal lift of gastrointestinal mucosal lesions in a patient undergoing a gastrointestinal endoscopic procedure.2. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 124.3. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 188.4. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 237.5. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 338.6. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 407.7. The pharmaceutical composition according to claim 1 , further comprising methylene blue or indigo carmine.8. The pharmaceutical composition according to claim 1 , further comprising sodium chloride.9. The pharmaceutical composition according to claim 1 , wherein the composition has a viscosity below about 150 centipoises.10. The pharmaceutical composition according to claim 1 , wherein the composition ...

MULTIPURPOSE MEMBRANES, METHODS FOR FORMING, AND APPLICATIONS THEREOF

One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.

Minimally invasive treatment of vertebra (MITV) using a calcium phosphate combination bone cement

Featured are a biocompatible, injectable, self-setting, cohesive, bone-bonding and remodeling calcium phosphate composite material and its use in methods of repairing defective bone, e.g., in vertebroplasty augmentation and kyphoplasty.

Bioadhesive for Soft Tissue Repair

The present invention provides compositions and methods for repair and reconstruction of defects and injuries to soft tissues. Some aspects of the invention provide tissue adhesives comprising a hybrid hydrogel by using a naturally derived polymer, gelatin and a synthetic polymer, polyethylene glycol, wherein the hydrogel is biocompatible, biodegradable, transparent, strongly adhesive to corneal tissue, and have a smooth surface and biomechanical properties similar to the cornea.

COMPOSITIONS COMPRISING EPITHELIAL CELLS FOR THE TREATMENT AND PREVENTION OF TISSUE ADHESIONS

Compositions and methods are described for the treatment and prevention of abdominal and thoracic adhesions as well as other adhesions using a cell-sustaining and surface-separating composition that nourishes and sustains grafted or present non-keratinizing (i.e. nonepidermal) epithelial cells. The composition is preferably a suspension of viable epithelial cells in a polymerizable, absorbable composition, such as fibrin glue, that will provide separation of the organ surfaces and nourishment to seeded and grafted cells.

BLOOD PRODUCTS WITH BINDING AGENT

A PROCESS FOR PREPARING AN AUTOLOGOUS PLATELET GEL AND MEMBRANES THEREOF

A process is disclosed for preparing an autologous platelet gel and membranes thereof comprising mixing a platelet concentrate with a calcium salt and batroxobin. This process encompassing the use of batroxobin as the gel activator allows to overcome the prior art processes drawbacks connected with the use for the same purpose of human of bovine thrombin. A kit is also described for carrying out this process.

ПОРОШКООБРАЗНЫЙ, ПОЛУСИНТЕТИЧЕСКИЙ МАТЕРИАЛ, ПОЛУЧЕННЫЙ ИЗМЕНЕНИЕМ СОСТАВА МОРСКОГО ПРИРОДНОГО БИОМАТЕРИАЛА, СПОСОБ ЕГО ПРОИЗВОДСТВА И ПРИМЕНЕНИЕ

Группа изобретений относится к области медицины, а именно к порошкообразному полусинтетическому материалу для изготовления заменителей кости, инъекционных цементов или цементов для герметизации эндопротезов или для изготовления устройств для биоабсорбируемого остеосинтеза и формованных имплантатов, полученному из морского природного биоматериала, с добавками нерастворимых и растворимых биополимеров и карбоната кальция, преобразованного карбонатизацией, где природный морской биоматериал представляет собой арагонитовый внутренний слой раковины двустворчатых моллюсков, выбранный из группы, включающей Pinctadines и Tricdacnes, а также относится к способу получения порошкообразного полусинтетического материала; к применению материала в качестве костного заменителя с приготовлением непосредственно перед применением для заживления или восстановления потерь вещества, лечения ожогов, струпьев, язв, эритемных кожных повреждений или для изготовления устройств или литых имплантатов; к применению карбоната ...

Verfahren zur Präparation von Knochenmaterial

The invention relates to a method for preparing bone material. According to said method, the demineralized bone material is subjected to an autolytic decomposition and an extraction of its cellular components while at the same time its osteoinductive matrix proteins are maintained. To this end, the bone material is incubated in a phosphate buffer solution in combination with a mixture of enzyme inhibitors. The dwelling time in the buffer solution does not exceed 24 hours.

BONE SPARE MATERIAL AND PROCEDURE FOR ITS PRODUCTION

TO THE USE IN MEDICINE AND SURGERY APTITUDE HALFSYNTHETIC MATERIAL

SYSTEM FOR THE PRODUCTION OF A GEL FROM AUTO+LIED BLOOD PANELS

ARZNEIMITTEL ZUR FÖRDERUNG DER WUNDHEILUNG

INJECT-CASH BONE SUBSTITUTE ON BASIS OF CALCIUM SALTS AND CELLS

COMPOSITION TO THE PRODUCTION, REGENERATION AND REPAIR OF FABRICS USING A CELL-BASIC BIOLOGICAL IMPLANT, WHICH IS ENRICHED WITH A BLOOD PANEL CONCENTRATE AND SUPPLEMENTEN

Semi-synthetic material for medical and surgical use

Semi-synthetic platelet gel and method for the preparation thereof

A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from 5 the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the 10 steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl 15 pyrrolidones, polysaccharides, and derivatives thereof. H:\iacindatkeensneci\n59320- Advance Holdinas Limited -noliqh tent doe 2n0/I/ ...

Viscoelastic composition

The purpose of the present invention is to provide: a viscoelastic composition that has excellent manipulability and is suitable for uses in which, when an opaque dark liquid accumulates inside a tube and obstructs the field of view of an endoscope, the liquid is pushed away, securing the field of view of the endoscope; and a method for securing the field of view of an endoscope which involves using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope contains water and a substance exhibiting viscoelastic properties, preferably has a hardness of 550 N/m ...

A process for preparing an autologous platelet gel and membranes thereof, and a kit for carrying out this process

Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof

The invention relates to a semi-synthetic powder material, derived from a natural marine biomaterial that is the inner aragonitic layer of the shell of bivalve molluscs chosen from the group comprising Pinctada, in particular Pinctada maxima and margaritifera, Tridacna, in particular Tridacna gigas, maxima, derasa, tevaroa, squamosa and crocea, Hippopus hippopus and Hippopus porcelanus, in powder form, supplemented with insoluble and soluble bio-polymers and calcium carbonate transformed by carbonation; it also relates to the method for preparing same and the uses thereof.

A PROCESS FOR PREPARING AN AUTOLOGOUS PLATELET GEL AND MEMBRANES THEREOF, AND A KIT FOR CARRYING OUT THIS PROCESS

A process is disclosed for preparing an autologous platelet gel and membranes thereof comprising mixing a platelet concentrate with a calcium salt and batroxobin. This process encompassing the use of batroxobin as the gel activator allows to overcome the prior art processes drawbacks connected with the use for the same purpose of human of bovine thrombin. A kit is also described for carrying out this process.

TISSUE FORMULATION OR ADHESIVE OBTAINED FROM A BLOOD COMPOSITION CONTAINING PLATELETS, AND METHOD FOR THE PREPARATION OF SAID FORMULATION

A formulation or tissular adhesive obtained from a platelet-rich blood composition and/or growth factors, and method for the preparation of this adhesive are disclosed. The preparation method of the adhesive comprises the steps of raising the temperature of the initial blood composition and subsequently activating the composition. Among other advantages, the tissular adhesive is biocompatible and biodegradable, has desirable biological or medical properties provided by the presence of platelets or growth factors, and also has a high adhesiveness and an accelerated coagulation process.

PLASMA-SUPPLEMENTED FORMULATION

Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof.

CALCIUM PHOSPHATE CEMENT COMPOSITIONS THAT SET INTO HIGH STRENGTH POROUS STRUCTURES

Calcium phosphate cement compositions are provided. Aspects of the cement compositions include a dry reactant component comprising a reactive a-tricalcium phosphate component, a multi-size pore forming calcium sulphate dihydrate component and a demineralized bone matrix component. During use, the dry reactant is combined with a setting fluid to produce a settable composition that sets into a high strength porous product. Aspects of the invention further include the settable compositions themselves as well as kits for preparing the same. Methods and compositions as described herein find use in a variety of applications, including hard tissue repair applications.

BONE CEMENT COMPOSITE CONTAINING PARTICLES IN A NON-UNIFORM SPATIAL DISTRIBUTION AND DEVICES FOR IMPLEMENTATION

MALLEABLE PASTE WITH ALLOGRAFT BONE REINFORCEMENT FOR FILLING BONE DEFECTS

The invention is directed toward a sterile malleable bone composition for application to a bone defect site to promote new bone growth at the site comprising a mixture of demineralized osteogenic bone powder with a particle size ranging from about 250 to about 750 microns and surface demineralized cortical bone rods having a diameter ranging from 1.0mm to 5.00mm or larger bone chips. The surface demineralized cortical bone rods have diameter to length ratio ranging from 1:2 to 1:20. The demineralized bone powder range from about 25 to about 30% of the weight of the composition and the cortical bone rods range from 5% to about 10% of the weight of the composition with the carrier being selected from the high molecular weight hydrogel in aqueous solution having a high molecular weight over 700,000 Daltons and ranging from about 2.0% to about 5.0% by weight of the carrier solution.

ACELLULAR MATRIX GLUE

An acellular matrix glue and a method of making is disclosed. Specifically, an acellular matrix glue that is useful in preparing a reinforced acellular matrix for medical applications including tissue engineering and hernia repair.

A PROLAMINE-PLANT POLAR LIPID COMPOSITION, ITS METHOD OF PREPARATION AND APPLICATIONS THEREOF

Dispersion containing prolamines and polar lipids of plant origin in an hydroalcoholic solvent useful to form a skin adhesive composition for use in pharmaceutical compositions.

BIOACTIVE POLYMERS EXTRACTED FROM A MARINE NATURAL BIOMATERIAL, THEIR MANUFACTURING PROCESSES AND APPLICATIONS

L'invention porte sur d'un biomatériau naturel marin leur procédé de préparation et sur leur utilisations.

OMITTED DEVICE FOR SUPPLYING GINSENG STEM CELLS TO COAPT SEVERED ORGAN

The present invention is an idea IP designed to solve a problem of regeneration. A scientific technique subfield of the present invention is regeneration. Prior to the present invention, a ginseng composition, coaptation gel, etc. Unlike the existing inventions, the present invention can be easily used by a user with a regenerative effect of ginseng to keep pace with a modern society. 1. using papers about regeneration. 2. producing goods at a 5% significance level by statistical verification with a meta analysis in an error calculation range with respect to the formula. 3. putting continuous calculation values in the formula 1 by applying the formula in real life. Hereby, a gel composition featuring a ginseng composition with respect to regeneration after severance can be prepared. COPYRIGHT KIPO 2016 ...

COMPOSITION FOR USE IN INDUCING BINDING BETWEEN PARTS OF LIVING MINERALISED TISSUE, PROCESS FOR ITS PREPARATION, PROTEIN FRACTION AND PHARMACEUTICAL COMPOSITION

A composition for use in inducing binding between parts of living mineralized tissue by regeneration of mineralized tissue on at least one of the parts, characterized in that it contains as an active constituent a protein fraction obtainable from a precursor to dental enamel, so called enamel matrix. The composition containing already defined proteine fraction, as an active substance, for use in treating periodontitis or diseases or conditions requiring regeneration of mineralised tissue. A process for preparing said composition is characterized by isolating tooth germs from mammal jaws, freeing said germs from enamel organ, recovering the enamel matrix from said freed germs, homogenizing the enamel matrix, separating a protein fraction from the homogenized enamel matrix and, optionally, mixing same with a carrier, diluent or adhesive acceptable for the purpose.

PROCESS AND DEVICE FOR THE PREPARATION OF PLATELET RICH PLASMA FOR EXTEMPORANEOUS USE AND COMBINATION THEREOF WITH SKIN AND BONE CELLS

The present invention is relates to a new platelet-rich plasma preparation, a method of preparation thereof, a use thereof, a device for the preparation thereof and preparations containing such a platelet-rich plasma preparation. Specifically, the invention provides platelet-rich plasma preparations for use in tissue regeneration and bone regeneration.

BONE PASTE

A bone paste useful in the orthopedic arts, for example in the repair of non-union fractures, periodontal ridge augmentation, craniofacial surgery, implant fixation, impaction grafting, or any other procedure in which generation of new bone is deemed necessary, is provided by a composition comprising a substantially bioabsorbable osteogenic compound in a gelatin matrix. In various embodiments, the osteogenic compound is selected from (i) demineralized bone matrix (DBM); (ii) bioactive glass ceramic, BIOGLASS, bioactive ceramic, calcium phosphate ceramic, hydroxyapatite, hydroxyapatite carbonate, corraline hydroxyapatite, calcined bone, tricalcium phosphate, or like material; (iii) bone morphogenetic protein, TGF-'beta', PDGF, or mixtures thereof, natural or recombinant; and (iv) mixtures of (i)-(iii).

Bonding of cartilaginous matrices using isolated chondrocytes

Methods of bonding cartilage pieces using new cartilage matrix generated by isolated chondrocytes in the presence of a biological gel. Also featured in the invention are cartilage implants used to repair cartilage defects.

Autologous platelet gel delivery system

The delivery system of the present invention is comprised of at least two chambers which store, individually, an activated blood component and an inactivated blood component. The first chamber comprises an activating agent and a filter which may be one in the same thus allowing the formed clot to be triturated thereby isolating the thrombin from the clot. The second chamber stores the inactivated blood component that when mixed with thrombin will produce a gel. The first or second chamber may further contain agents which are desired to be delivered to a specific site. The unique design of the delivery system allows for ease in operation of combining two agents at a specific time and place.

Multipurpose membranes, methods for forming, and applications thereof

One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.

Methods and compositions for achieving hemostasis and stable blood clot formation

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering

The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same.

Medical absorbable hemostatic material for bone wounds and preparation method therefor

A medical absorbable hemostatic and wound healing promoting material for bone wounds and a preparation method thereof. The absorbable hemostatic material for bone wounds is formed of 40-95% of a base material and 5-60% of an adjuvant, based on weight percent, wherein the base material is an oligosaccharide, a polysaccharide, or a mixture of the oligosaccharide and the polysaccharide, and the adjuvant includes (1) one or more polyhydric alcohols, (2) one or more vegetable oils, and (3) one or more emulsifying agents. The method for preparing the absorbable hemostatic and wound healing promoting material for bone wounds comprises mixing a base material and an adjuvant at prescribed amounts by chemical blending or latex blending, cooling to form a solid lump, packaging, and sterilizing.

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A kit comprising a pharmaceutical composition in a container , wherein the pharmaceutical composition comprises:(a) at least one poloxamer selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, or a mixture thereof; and(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C. in vitro.2. The kit according to claim 1 , wherein the container is selected from an ampoule claim 1 , a vial claim 1 , a bottle claim 1 , and a pre-filled syringe.3. The kit according to claim 2 , wherein the container is an ampoule.4. The kit according to claim 3 , wherein the ampoule contains from 10 mL to 50 mL of the pharmaceutical composition.5. The kit according to claim 2 , wherein the container is a vial.6. The kit according to claim 5 , wherein the vial contains from 10 mL to 50 mL of the pharmaceutical composition.7. The kit according to claim 2 , wherein the container is a bottle.8. The kit according to claim 2 , wherein the container is a pre-filled syringe.9. The kit according to claim 8 , wherein the pre-filled syringe contains from 5 mL to 10 mL of the pharmaceutical composition.10. A method for creating a cushion in a submucosal tissue in the gastrointestinal tract of a patient claim 8 , comprising injecting into the submucosal tissue a pharmaceutical composition comprising:(a) at least one poloxamer selected from poloxamer 124, ...

Minced Cartilage Systems and Methods

Compositions comprising a plurality of cartilage particles from a human adult cadaveric donor, wherein the cartilage particles comprise viable chondrocytes, and a biocompatible carrier are provided. Methods of manufacturing cartilage compositions comprising a plurality of cartilage particles from a human adult cadaveric donor are also provided.

Hydratable and flowable implantable compositions and methods of making and using them

Implantable bone compositions are provided. The implantable compositions comprise hydratable bone putties. The hydratable bone putties comprise porous ceramic granules having an average diameter from about 50 μm to 800 μm. The porous ceramic granules comprise hydroxyapatite and beta-tricalcium phosphate. The implantable bone compositions further include collagen carriers. In some embodiments, the hydratable bone putty can be hydrated to form a non-settable flowable cohesive cement or gel. Methods of making and using the implantable compositions are also provided.

INTRAOPERATIVE AND BLOOD DERIVED ADHESIVES

The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency. 1. An isolated hydrogel composition comprising a blood product and an amine-reacting proteoglycan.2. An isolated hydrogel composition produced by incubating an isolated blood product with an amine-reacting proteoglycan.3. The isolated hydrogel composition of claim 2 , wherein said hydrogel is further hydrated after said blood product is contacted with said amine-reacting proteoglycan.4. (canceled)5. The isolated hydrogel composition of claim 2 , wherein said amine-reacting proteoglycan is imidated.6. The isolated hydrogel composition of claim 5 , wherein said amine-reacting proteoglycan is chondroitin sulfate claim 5 , hyaluronic acid claim 5 , dextran claim 5 , carboxy methyl starch claim 5 , keratin sulfate claim 5 , or ethyl cellulose.7. The isolated hydrogel composition of claim 3 , wherein said amine-reacting proteoglycan is chondroitin sulfate succinimidyl succinate or N-hydroxysuccinimide (NHS) hyaluronic acid.8. The isolated hydrogel composition of claim 1 , wherein said blood product is present at between 25% and 75% volume to volume (v/v).9. The isolated hydrogel composition of claim 6 , wherein said amine-reacting proteoglycan is present at between 5% and 20% weight to volume (w/v).10. The isolated hydrogel composition of claim 9 , further comprising heparin.11. ( ...

Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis

Bone filler compositions, methods of making and using the same, and methods of treating osteoporosis and cancer-induced bone defects, are described.

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 130-. (canceled)31. A sterilized , vacuum sealed separator tube for preparing a therapeutic platelet concentrate from whole blood comprising:an inlet adapted to introduce whole blood;an anticoagulant composition comprising either: (i) a sodium citrate solution; or (ii) anhydrous sodium citrate; anda thixotropic gel selected from a polyester-based gel or a polymer mixture gel, the thixotropic gel being water insoluble and chemically inert to blood constituents;{'sup': '12', 'wherein the separator tube is adapted to be centrifuged when at least partially filled with the whole blood, at about 1,500 g up to about 2,000 g for about 3 to about 10 minutes in a single centrifugation to separate blood components in the whole blood into at least: (i) the therapeutic platelet concentrate obtained without supernatant removal and containing greater than 300 billion platelets per liter and less than about 0.6×10red blood cells per liter; and (ii) red blood cells.'}32. The separator tube according to claim 31 , wherein the anticoagulant composition comprises a 0.1 M sodium citrate solution.33. The separator tube according to claim 31 , wherein the anticoagulant composition comprises anhydrous sodium citrate.34. The separator tube according to claim 31 , wherein the thixotropic gel is a polyester-based gel.35. The separator tube according to claim 31 , wherein the separator tube is comprised at least of polyethylene terephthalate (PET).36. (canceled)37. ( ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A method of treating a patient with platelet rich plasma , the method comprising:withdrawing blood from the patient;centrifuging the blood in a centrifugation tube containing a thixotropic gel and an anticoagulant, the thixotropic gel being configured to separate platelet rich plasma, the centrifuging being performed for a length of time such that the thixotropic gel forms a barrier between plasma and erythrocytes;removing the platelet rich plasma from the tube; andadministering the platelet rich plasma to the patient.2. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force between about 1500 g and about 2000 g for about 3 to 10 minutes.3. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force of at least 1500 g for at least 8 minutes.4. The method of claim 1 , further comprising separating the platelet rich plasma by removing approximately half of a supernatant containing platelet poor plasma.5. The method of claim 4 , further comprising re-suspending the platelet rich plasma in the tube claim 4 , wherein said re-suspending follows said separating the platelet rich plasma.6. The method of claim 1 , further comprising admixing the platelet rich plasma with a coagulation activator claim 1 , wherein the coagulation activator comprises at least one of: a thrombin activator claim 1 , a fibrinogen activator claim 1 , a calcium claim 1 , a calcium salt claim 1 , a CaCl ...

Hemostatic device

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

DEVICES AND METHODS FOR ENDOSCOPIC PATCH DELIVERY

Systems and methods of delivering a patch to a target site of a patient are described herein. The patch may comprise a biomaterial such as chitosan or extracellular matrix and may be biocompatible and/or bioresorbable. The system may include an endoscope, a patch, and one of an instrument or a cap, the patch being coupled to the respective instrument or cap and detachable therefrom. Methods of delivering the patch to the target site may include introducing an endoscope into a gastrointestinal tract of a patient, e.g., the patch being in a folded or crimped configuration, navigating a distal end of the endoscope proximate a target site; and applying the patch to the target site while releasing the patch from the endoscope. 1. A method of delivering a patch to a target site of a patient , the method comprising:introducing an endoscope into a gastrointestinal tract of a patient, wherein the endoscope includes a patch in a folded or crimped configuration, the patch comprising a biocompatible material;positioning a distal end of the endoscope proximate a target site; andapplying the patch to the target site while releasing the patch from the endoscope.2. The method of claim 1 , wherein the target site includes a laceration in tissue following endoscopic mucosal resection (EMR) claim 1 , endoscopic submucosal dissection (ESD) claim 1 , or tissue biopsy; or wherein the target site includes an anastomosis.3. The method of claim 1 , wherein the patch comprises chitosan claim 1 , extracellular matrix claim 1 , or a combination thereof.4. The method of claim 1 , further comprising introducing an instrument comprising a shaft into a working channel of the endoscope claim 1 , the patch being disposed on a distal end of the instrument.5. The method of claim 4 , wherein applying the patch to the target site includes unrolling the patch from the distal end of the instrument.6. The method of claim 4 , wherein the distal end of the instrument includes a cylinder claim 4 , the patch ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A medical separator system for preparation of a platelet concentrate , comprising: a thixotropic gel being adapted to separate blood components in whole blood to provide a platelet concentrate containing less than or equal to 1% hematocrit and a pellet containing more than or equal to 99% hematocrit by forming a barrier between plasma and erythrocytes when said tube is centrifuged; and', 'an anticoagulant being adapted to at least reduce coagulation of said whole blood., 'a tube being adapted to be centrifuged for a length of time and containing two additives, wherein said two additives include2. The medical separator system of claim 1 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate containing 2 or more times a normal level of platelets and growth factors compared to said whole blood.3. The medical separator system of claim 2 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate with platelet recovery of 95%±5%.4. The medical separator system of claim 3 , wherein no other additives are contained in said tube.5. A kit comprising:{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'a medical separator system of ; and'}an applicator device for applying said platelet concentrate to a patient for medical, therapeutic, or skincare application.6. The medical separator system of claim 3 , ...

INTRAOPERATIVE USES OF SETTABLE SURGICAL COMPOSITIONS

Provided herein are settable surgical compositions and methods for their intraoperative use. 1. A method for spinal fusion , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC , optionally dividing the HPC into two or more additional portions , and inserting a first portion of the HPC into an intervertebral space to form a spacer or cage.2. The method of claim 1 , further comprising introducing one or more of an autograft material claim 1 , an allograft material claim 1 , or a bone substitute material into one or more holes drilled into the HPC spacer or cage.3. The method of claim 1 , further comprising applying a second portion of the HPC to two or more spinal pedicles adjacent to the HPC spacer or cage to form two or more HPC anchor points on the pedicles and either stretching a further additional portion of the HPC between the anchor points or positioning a rod between the anchor points and pressing the rod into the anchor points claim 1 , thereby connecting the anchor points.4. A method for stabilizing surgical hardware claim 1 , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC optionally dividing the HPC into two or more additional portions claim 1 , and applying a first portion of the HPC between the surface of a bone and the joint hardware claim 1 , applying a second portion of the HPC across the surface of the joint hardware after it has been affixed to the bone claim 1 , or applying a first portion of the HPC between the surface of a bone and the joint hardware and applying a second portion of the HPC across the surface of the joint hardware after it has been affixed to the bone.5. A method for stabilizing a surgical screw claim 1 , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC claim 1 , filling a drilled or tapped hole with a portion of the HPC claim 1 , and inserting the screw into the HPC before it ...

Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients

The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same. 1. A blood clotting composition comprising:isolated platelet microparticles; one or more factors selected from fibrinogen (Factor I), von Willebrand factor, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Protein C (PC), Protein S (PS), antithrombin III (ATIII); and a pharmaceutical carrier;wherein fibrinogen is at about 10-1000 mg/deciliter (dL), Factor V is at about 0.5-2.0 International Unit (IU), Factor VII is at about 0.5-4.0 IU, Factor VIII is at about 0.2-2.0 IU, Factor IX is at about 0.5-3.0 IU, Factor XI is about 0.5-3.0 IU, Factor XII is at about 1.0-7.0 IU, Protein C (PC) is at about 25-300% activity, Protein S (PS) is at about 10-150% activity, antithrombin III (ATIII) is about 25-250% activity.2. The composition of claim 1 , wherein the composition has either prothrombin time that is within a normal reference range or an activated partial thromboplastin time that is within a normal reference range.3. (canceled)4. The composition of claim 1 , wherein the composition has a blood clot initiation time (R-time) of less than three minutes when measured using thromboelastography.5. The composition of claim 1 , wherein the concentration of platelet microparticles in the composition is >10″ microparticles/μl.6. The composition of claim 1 , wherein the composition comprises two or more of the factors or all eight factors.7. (canceled)8. The composition of claim 1 , wherein the composition is formulated for topical administration or systemic administration.9. The composition of claim 8 , wherein the composition is formulated as a spray claim 8 , powder claim 8 , cream claim 8 , gel claim 8 , or ointment.10. (canceled)11. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the blood clotting composition of and'}a wound dressing ...

Minced cartilage systems and methods

Compositions comprising a plurality of cartilage particles from a human adult cadaveric donor, wherein the cartilage particles comprise viable chondrocytes, and a biocompatible carrier are provided. Methods of manufacturing cartilage compositions comprising a plurality of cartilage particles from a human adult cadaveric donor are also provided.

EMBOLIC MATERIAL AND METHOD FOR PRODUCING SAME

An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium. 1. An embolic material comprising:at least one type of polymer: anda liposoluble contrast medium.2. The embolic material according to claim 1 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.3. The embolic material according to claim 1 ,wherein the polymer is biodegradable.4. The embolic material according to claim 1 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate.5. A method for producing an embolic material claim 1 , the method comprising:extruding a raw material containing at least one type of polymer and a liposoluble contrast medium into a solvent, the raw material being in a molten state; andcooling the raw material so as to solidify the raw material.6. The method for producing an embolic material according to claim 5 ,wherein the raw material extruded into the solvent forms spherical shapes.7. The method for producing an embolic material according to claim 5 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.8. The method for producing an embolic material according to claim 5 ,wherein the polymer is biodegradable.9. The method for producing an embolic material according to claim 5 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate. This international application claims the ...

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A pharmaceutical composition in the form of an emulsion or a microemulsion comprising:(a) an aqueous phase;(b) an oily phase;(c) at least one surfactant;(d) at least one of poloxamer 188, poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407; and(e) at least one physiologically acceptable excipient;wherein said at least one of poloxamer 188, polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below the critical gelation concentration (CGC), and wherein said composition remains in liquid phase up to a temperature of about 40° C. in vitro.2. The pharmaceutical composition according to claim 1 , wherein said composition has a viscosity below about 150 cP (centipoises).3. The pharmaceutical composition according to claim 1 , wherein said at least one of poloxamer 188 claim 1 , poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below about 15% by weight claim 1 , with respect to the weight of the composition.4. The pharmaceutical composition in form of emulsion or microemulsion according to claim 1 , wherein said at least one of poloxamer 188 claim 1 , polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount between about 5% and about 11% by weight claim 1 , with respect to the weight of the composition.5. The pharmaceutical composition according to claim 1 , wherein said poloxamer 407 is present in ...

HEMOSTATIC DEVICE

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce homeostasis at an anatomical site. 127-. (canceled)28. A method for accelerating hemostasis comprising:applying to a site of injury, a bioresorbable hemostatic device comprising a compressed, particularized, dehydrated extracellular matrix material (ECM) wafer derived from an epithelial tissue, one or more ECM components in their native configuration, and a sheet like backing comprising an ECM that is applied to said wafer; and,applying a pressure to the hemostatic device.29. The method of wherein the applied pressure is substantially a constant pressure which is applied continuously or intermittently over a periodic time.30. The method of wherein said hemostasis begins at least at 30 seconds after application of the hemostatic device to the site of injury.31. The method of wherein the applied bioresorbable hemostatic device is not removed from the injury site until hemostasis is achieved.32. The method of wherein the site of injury is selected from the group consisting of lung claim 28 , heart claim 28 , muscle claim 28 , liver claim 28 , kidney claim 28 , spleen claim 28 , intracranial claim 28 , intrathoracic claim 28 , intra-abdominal claim 28 , intramedullary claim 28 , intramuscular and intrathecal.33. The method of wherein the hemostatic device comprises a gel wherein the gel is introduced into a site claim 28 , wound or body orifice selected from the group consisting of uterus medullary cavity claim 28 , nasal passage claim 28 , nasal sinus claim 28 , auditory canal claim 28 , cervix claim 28 , and tooth socket where said injury site is located.34. The method of wherein the gel is introduced into the lumen of a vessel at the site of injury.35. The method of wherein said ECM is non-cross-linked.36. The method of wherein the hemostatic device comprises a tampon introduced into the site of injury selected from the group ...

Compositions and methods for adhesion to surfaces

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

HEMOSTATIC DEVICE

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site. 127-. (canceled)28. A bioresorbable hemostatic device , comprising: (i) a compressed , dehydrated , particularized , extracellular matrix material (ECM) comprising ECM components isolated in their native configuration; and , (ii) a sheet like backing comprising the ECM that is applied to the surface of the ECM of (i).29. The device of wherein said ECM component is selected from the group consisting of collagen type IV claim 28 , collagen type VII claim 28 , glycosaminoglycans claim 28 , fibronectin claim 28 , and laminin claim 28 , and a combination thereof.30. The device of wherein said ECM is selected from the group consisting of urinary bladder submucosa (UBS) claim 28 , liver-derived biomatrix (LBM) claim 28 , and small-intestine submucosa (SIS) claim 28 , urinary bladder matrix (UBM) and small intestinal matrix (SIM).31. The device of wherein said particularized ECM material comprises a disc.32. The device of further comprising a bioresorbable polymer lattice and said ECM of (ii) claim 28 , wherein said ECM of (ii) is selected from the group consisting of a gel claim 28 , foam claim 28 , or a powder.33. The device of wherein said bioresorbable polymer lattice comprises a plurality of spaces wherein said plurality of spaces are filled with said ECM.34. The device of wherein the sheet like backing comprising the ECM that is applied to the surface of said comprised claim 28 , dehydrated claim 28 , particularized ECM comprises a density ranging from about 10 mg/cmto about 600 mg/cm.35. The device of wherein said device is a balloon hemostatic device.36. The device of wherein said compressed claim 28 , dehydrated particularized ECM of (i) comprises a gel.37. The device of wherein said sheet like backing is applied to said gel.38. The device of wherein said sheet like backing comprises ...

COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING

Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds. 1. A fibrin sealant comprising a fibrinogen complex (FC) component , a thrombin component , and a cellular component , wherein concentration of fibrinogen used to form the gel is between from about 2 to about 5 mg/ml , wherein the cellular component comprises one or more of stem/progenitor cells , and wherein the fibrin sealant comprises at least 1.5-2.0×10stem/progenitor cells/cm.2. The composition of claim 1 , stem/progenitor cells are selected from the group consisting of bone marrow derived cells claim 1 , hematopoietic stem cells claim 1 , mesenchymal stem cells claim 1 , peripheral blood stem cells claim 1 , and mixtures and combinations thereof.3. The composition of claim 1 , wherein the stem/progenitor cells are bone marrow derived cells.4. The composition of claim 1 , wherein the stem/progenitor cells are mesenchymal stem cells.5. The composition of claim 1 , wherein the stem/progenitor cells are peripheral blood stem cells.6. A method of using a fibrin sealant claim 1 , comprising: a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant claim 1 , said fibrin sealant comprising calcic thrombin and fibrinogen claim 1 , wherein the concentration of calcic thrombin is about 25 U/ml claim 1 , wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml claim 1 , and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×10stem/progenitor cells/cm; b) administering the fibrin sealant to a cutaneous wound claim 1 , wherein the fibrin sealant is administered in the form of a polymerized gel or spray.7. The method of claim 6 , wherein the fibrin sealant is administered to the site of the wound at least two times over the span of three weeks.8. The method of claim 6 , stem/progenitor cells are bone marrow derived cells ...

RADIOACTIVE LIQUID EMBOLIC

Liquid embolic preparations and medical treatment methods of using those preparations are described. In some embodiments, the preparations or solutions can transition from a liquid to a solid for use in the embolization. The preparations can include biocompatible polymers with covalently bound radioactive iodine isotopes. 1. A polymeric composition comprising:a substantially stable biocompatible polymer comprising a reaction product of:a first monomer including a polymerizable moiety having a linkage to a visualization agent having at least one aromatic ring, wherein the at least one aromatic ring includes at least one iodine atom, wherein at least one of the at least one iodine atom is a radioactive isotope,and a second monomer including a polymerizable moiety and at least one hydroxyl group; anda non-physiological solution;wherein the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution.2. The polymeric composition of claim 1 , wherein the linkage is biodegradable.3. The polymeric composition of claim 1 , further including folic acid or a functionalized form thereof.4. The polymeric composition of claim 1 , wherein the radioactive isotope is I claim 1 , I claim 1 , I claim 1 , I claim 1 , or a combination thereof.5. The polymeric composition of claim 1 , wherein the radioactive isotope is I.6. The polymeric composition of claim 1 , wherein the radioactive isotope is I.7. The polymeric composition of claim 1 , wherein the radioactive isotope is I.8. The polymeric composition of claim 1 , wherein the radioactive isotope is I.9. The polymeric composition of claim 1 , wherein the first monomer is functionalized triiodophenol claim 1 , 1-((2-(methacryloyloxy)ethoxy)carbonyloxy)ethyl-3 claim 1 ,5-diacetamido-2 claim 1 ,4 claim 1 ,6-triiodobenzoate claim 1 , 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate claim 1 , or a ...

CLOTTING CASCADE INITIATING APPARATUS AND METHODS OF USE AND METHODS OF CLOSING WOUNDS

Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site to complete clotting. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed. 1. A method of closing a wound in a patient , the method comprising the steps of:a) treating a blood fluid such that at least a portion of the blood fluid will form a clot of blood subsequent to the treatment, the blood fluid containing sufficient blood components to enable a portion of the blood fluid to clot subsequent to the treatment once a clotting cascade is initiated, the blood components being selected from the group consisting of whole blood, natural components of whole blood, whether derived from whole blood, blood extracts, or products of ex-vivo cell cultures, and procoagulating agents which assist in or enhance the clotting or coagulation of the blood fluid, the step of treating the blood fluid including initiating the clotting cascade; andb) transporting the treated blood fluid to the wound in the patient such that the blood fluid can come into contact with the patient proximate the wound and the clotting cascade can come generally to a conclusion and a clot can form proximate the wound such that a clot is formed in the wound which prevents fluid from passing through the wound.2. The method of claim 1 , the step of treating the blood fluid including (1) providing a containment chamber in which the blood fluid can be contained claim 1 , (2) placing the blood fluid in the containment chamber; and (3) initiating the clotting cascade by exposing the blood fluid to a procoagulating agent within the containment chamber.3. The method of ...

USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERING

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia. 1. A composition comprising photosynthetic cells.2. The composition of claim 1 , wherein the photosynthetic cells are algae cells.3. The composition of claim 2 , wherein the algae cells are unicellular algae cells.4Chlamydomonas.. The composition of claim 3 , wherein the unicellular algae cells are from the genus5ChlamydomonasChlamydomonas reinhardtii.. The composition of claim 4 , wherein the is6. The composition of claim 1 , wherein the photosynthetic cells are encapsulated with a permeable immunologically inert material.7. The composition of claim 6 , wherein the permeable immunologically inert material is a natural or synthetic polymer.8. The composition of claim 7 , wherein the natural or synthetic polymer is a hydrogel or alginate.9. The composition of claim 1 , wherein at least some of the photosynthetic cells are genetically engineered cells.10. The composition of claim 5 , wherein at least some of the photosynthetic cells have been genetically engineered to contain nucleic acids encoding for at least one bioactive molecule.11. The composition of claim 1 , for use ex vivo.12. The composition of claim 1 , for use in vivo.13. A composition comprising photosynthetic cells configured for use claim 1 , in a subject claim 1 , in a method selected from the group consisting of: treatment of hypoxia; treatment of ischemia claim 1 , in vivo implantation claim 1 , treatment or prevention of inflammation claim 1 , treatment of damage of tissue selected from skin claim 1 , nerve claim 1 , bone claim 1 , cartilage or blood tissue.14. The composition of claim 13 , for use ex vivo.15. The composition of claim 11 , for use in vivo. This application is a divisional of U.S. patent application Ser. No. 14/869,930, filed on Sep. 29, 2015, which is a continuation of U.S. patent application Ser. No. 13/636,402, filed on Dec. 20, ...

FIBRIN AND/OR DIALDEHYDE STARCH HYDROLYSATE MATERIALS, AND PREPARATION AND USE THEREOF

Various compositions of matter, methods of making compositions of matter, and methods of using compositions of matter, e.g. for inducing hemostasis, are disclosed. In some embodiments, a starting fibrin material is subjected to controlled hydrolysis, desirably base-catalyzed, to prepare a fibrin hydrolysate material with increased water sorption capacity. Such fibrin hydrolysate materials, alone or combined with one or more additional substances, can be used in the preparation of hemostasis promoting foams, powders or gels. In some embodiments, a starting dialdehyde starch material is subjected to controlled hydrolysis to prepare a dialdehyde starch hydrolysate material. Such dialdehyde starch hydrolysate materials, alone or combined with one or more additional substances, in some cases combined with a fibrin hydrolysate material, can be used in the preparation of hemostasis promoting foams, powders or gels. 1. A method for making a hemostasis promoting material , comprising:subjecting a fibrin-containing starting material to hydrolysis conditions so as to form a fibrin hydrolysate material having an increased sorption capacity, relative to the fibrin starting material, for water at a pH of 7.2. The method according to claim 1 , wherein the hydrolysis conditions comprise contacting the fibrin starting material with a basic liquid medium and/or wherein the fibrin hydrolysate material exhibits a sorption capacity for water at a pH of 7 and a temperature of 20° C. of at least about 10 times its dry weight.3. The method according to claim 1 , wherein the basic liquid medium has a pH in the range of about 10 to 14 and/or wherein the basic liquid medium comprises sodium hydroxide or potassium hydroxide.4. (canceled)5. The method of claim 1 , also comprising lyophilizing the fibrin hydrolysate material.6. (canceled)7. The method of claim 1 , wherein the subjecting is for a period of time of at least about 10 minutes claim 1 , more preferably wherein the period of time is ...

BIOACTIVE BONE GRAFT SUBSTITUTES

Provided are synthetic bone graft substitutes that include bioactive glass and a carrier. Synthetic bone graft substitutes may include bioactive glass, glycerol and polyethylene glycol. Also provided are bone graft substitutes that include collagen and bioactive glass particles. Example bone graft substitutes may include collagen and bioactive glass particles. Other example embodiments may include Type I Bovine Collagen, an angiogenic agent, such as hyaluronic acid, and bioactive glass. Further provided are methods that include administering the present bone graft substitutes to a mammal, e.g., by surgical insertion of the bone graft substitute into the mammal, either alone or in conjunction with one or more implant devices. Further provided are kits that include the present bone grafts. 1. A method of making a bone graft substitute , the method comprising:providing a bone graft substitute in a dry form, the bone graft substitute comprising a carrier in the form of a semi-rigid collagen-based scaffold comprising 5-20% by weight of collagen and 0.1-10% by weight of an angiogenic agent, wherein the carrier is free of glycerol and polyethylene glycol, and 84% by weight of bioactive glass particles; andhydrating the dry form of the bone graft substitute to form a moldable putty.2. The method of claim 1 , wherein after the bone graft substitute is hydrated to form the moldable putty claim 1 , the bone graft substitute retains a porosity of 150 to 450 μm.3. The method of claim 1 , wherein the angiogenic agent comprises one or more polysaccharides.4. The method of claim 1 , wherein the angiogenic agent comprises hyaluronic acid.5. The method of claim 1 , wherein the collagen is type I bovine collagen.6. The method of claim 1 , wherein the bone graft substitute is free of a calcium ceramic component.7. The method of claim 1 , wherein the collagen is present at 17-20% by weight.8. The method of claim 1 , wherein the angiogenic agent is present at 1-5% by weight.9. The method ...

METHODS AND COMPOSITIONS FOR TISSUE ADHESIVES

Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue. 134.-. (canceled)35. A bioadhesive composition comprising:a photothermally responsive composition comprising collagen, silk protein, or a combination thereof chemically conjugated to a light absorbing chromophore,wherein the light absorbing chromophore is entrapped within the collagen, silk protein, or combination thereof.36. The bioadhesive composition of claim 35 , wherein the light absorbing chromophore comprises silver nanoparticles claim 35 , gold nanorods claim 35 , or gold nanoparticles claim 35 , or mixtures thereof.37. The bioadhesive composition of claim 35 , wherein the bioadhesive composition further comprises an active agent claim 35 , cells claim 35 , or a combination thereof.38. The bioadhesive composition of claim 37 , wherein the active agent comprises an antibacterial agent.39. The bioadhesive composition of claim 37 , wherein the active agent comprises an MMP inhibitor claim 37 , a soluble factor claim 37 , a cytokine claim 37 , or a growth factor.40. The bioadhesive composition of claim 39 , wherein the soluble factor comprises FGF (fibroblast growth factor) claim 39 , TGF-beta claim 39 , EGF or other factors known as growth factors or cytokines claim 39 , or known to be involved in wound healing and repair.41. A bioadhesive composition comprising:a photothermally responsive composition comprising collagen, silk protein, or a combination thereof chemically conjugated to a light absorbing chromophore,wherein the light absorbing chromophore is entrapped within the collagen, silk protein, or combination thereof,wherein the light absorbing chromophore is configured to convert light to heat upon the application of an effective amount of a directed light beam to the bioadhesive composition, ...

INTRAOPERATIVE USES OF SETTABLE SURGICAL COMPOSITIONS

Provided herein are settable surgical compositions and methods for their intraoperative use. 1. A method for joining pieces of cut or fractured bone , the method comprisingintraoperatively mixing two or more individual reactive putties to form a homogenous putty composition (HPC),optionally dividing the HPC into two or more additional portions,applying a first portion of the HPC to the cut or fractured surface of at least one of the pieces of bone, andmaintaining the pieces of cut or fractured bone in proximity to form a reduced fracture until the HPC has hardened and the reduced fracture remains fixed.2. The method of claim 1 , wherein the first portion of the HPC is applied to the cut or fractured surface of the at least one of the pieces of bone in multiple portions at a plurality of locations of the cut or fractured surface and interrupted by gaps.3. The method of claim 1 , wherein the first portion of the HPC is applied to the cut or fractured surface of the at least one pieces of bone as a single portion across substantially the entire length of the cut or fractured surface.4. The method of claim 1 , further comprising compressing the pieces of cut or fractured bone together until the first portion of the HPC has hardened.5. The method of claim 1 , wherein the pieces of cut or fractured bone are maintained in proximity for about 2 to 5 minutes.6. The method of claim 1 , wherein the method further comprises applying a second portion of the HPC across the reduced fracture line in the form of a plate or tape.7. The method of claim 1 , wherein the method further comprises pressing additional portions of the HPC into each of two or more drill holes located opposite each other across the reduced fracture line claim 1 , thereby substantially filling each drill hole.8. The method of claim 7 , wherein the method further comprises shaping an additional portion of the HPC into a rod and joining each end of the rod to a portion of the HPC pressed into a drill hole.9. The ...

PHOSPHOCALCIC CEMENT COMPOSITION COMPRISING BLOOD

A bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed. 1. A bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm , and a liquid component comprising blood.2. The bone cement paste of claim 1 , wherein the liquid component is blood.3. The bone cement paste of claim 1 , wherein the powder component further comprises at least one calcium phosphate compound other than α-TCP.4. The bone cement paste of claim 3 , wherein the calcium phosphate compound is selected from the group consisting of hydroxyapatite (HA) claim 3 , amorphous calcium phosphate (ACP) claim 3 , monocalcium phosphate anhydrous (MCPA) claim 3 , monocalcium phosphate monohydrate (MCPM) claim 3 , dicalcium phosphate dihydrate (DCPD) claim 3 , dicalcium phosphate anhydrous (DCPA) claim 3 , precipitated or calcium-deficient apatite (CDA) claim 3 , β-tricalcium phosphate (β-TCP) claim 3 , tetracalcium phosphate (TTCP) claim 3 , and mixtures thereof.5. The bone cement paste of any one of claim 1 , wherein the powder component comprises:α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, andat least one calcium phosphate compound selected from the group consisting of: MCPM, DCPD, CDA, and mixtures thereof.6. The bone cement paste of claim 1 , wherein the powder component comprises at least 70% by weight of α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm claim 1 , in relation to the total weight of said powder component.7. The bone cement paste of claim 1 , wherein the powder component comprises:α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μmMCPM, ...

METHODS AND SYSTEMS FOR THERMOEMBOLIZATION

Thermoembolization systems and techniques may provide simultaneous embolization and ablation of bodily tissue. In some embodiments, thermoembolization may be induced, for example, by arterially infusing a viscous liquid carrying an electrophilic material into the feeding vessel(s) of a tumor. The viscous liquid serves to occlude the arterial supply to the tumor while the electrophilic material concurrently undergoes an exothermic reaction when it comes into contact with water present in bodily tissues. In result, thermoembolization induces simultaneous hypoxic and thermal stresses to the tumor, thereby overwhelming tumor cells. 1. A thermoembolization system for treating a tissue , the thermoembolization system comprising:a percutaneous liquid delivery catheter defining at least one lumen extending from a proximal portion of the percutaneous liquid delivery catheter to a distal portion of the percutaneous liquid delivery catheter, the distal portion of the percutaneous liquid delivery catheter configured for insertion into an arterial vessel such that a distal tip of the distal portion of the percutaneous liquid delivery catheter is positionable adjacent the tissue;a liquid dispensing device including a reservoir and a portion that is configured to releasably couple with the proximal portion of the percutaneous liquid delivery cannula such that the liquid dispensing device can inject a liquid from the reservoir into the lumen of the percutaneous liquid delivery catheter; anda thermoembolic liquid contained within the reservoir, wherein the thermoembolic liquid has a viscosity sufficient to cause an occlusion of a microvasculature of the tissue, and wherein the thermoembolic material includes a reagent that exothermically reacts with a substance.2. The thermoembolization system of claim 1 , wherein the reagent comprises calcium oxide.3. The thermoembolization system of claim 2 , wherein the substance is water.4. The thermoembolization system of claim 1 , wherein the ...

One component fibrin glue comprising zymogens

Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use

Disclosed are mesenchymal stem cell growth factor compositions and methods of their use to treat skin disorder, alleviate the effects of aging, treat wounds, orthopedic disorders, sexual dysfunction and/or reduce inflammation.

Fluorapatite glass-ceramics

The present invention provides a highly-sintered fluorapatite glass-ceramic comprising a high Ca/Al or Sr/Al mole-ratio, that possesses a microstructure that induces apatite/bone deposition.

METHOD FOR USING AN ADHESIVE COMPOSITION IN BONE PRESERVATION AND AUGMENTATION

A method comprising the steps of applying an adhesive composition to a substrate bone repair region. The adhesive composition comprises a porous, biocompatible, biodegradable, resorbable, non-toxic, and polymerizable composition. The substrate bone repair region comprises a bone structure, implant or device surface, or tooth surface. The adhesive composition is cured to provide a polymerized adhesive composition resulting in repairing or augmenting the substrate bone repair region. The adhesive composition may be mixed with a bone graft material before application. The adhesive composition may be additionally applied to a barrier membrane that is placed over the substrate bone repair region where the adhesive composition or combination of adhesive composition and bone graft material is applied. 1. A method comprising the steps of:applying an adhesive composition to a substrate bone repair region, said adhesive composition comprises at least a bovine serum albumin or collagen based adhesive;wherein said bovine serum albumin or collagen based adhesive composition comprises at least a porous, biocompatible, biodegradable, resorbable, or polymerizable adhesive composition;wherein said substrate bone repair region comprises at least one of a bone structure, an implant device surface, and a tooth surface;curing said bovine serum albumin or collagen based adhesive composition applied to said substrate bone repair region with a curing device employing at least light curing or chemical curing;wherein said curing step is configured to generate a polymerized bovine serum albumin or collagen based adhesive composition on said substrate bone repair region; andwherein said curing step is further configured to be operable for at least one of repairing said bone structure, filling gaps between said bone structure or implant device surface, and filling gaps between said bone structure or tooth surface.2. The method of claim 1 , wherein said bovine serum albumin or collagen based ...

Extracellular matrix for tissue reconstruction of mucosal tissue

Described are methods and compositions for treatment of reproductive or urogenital mucosal tissue damage using Extracellular Matrix (ECM) solution and, particularly, Extracellular Matrix Hydrogel (ECMH) solution delivered to the target site for tissue repair, restoration, remodeling, or reconstruction.

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

BONE PASTES COMPRISING BIOFUNCTIONALIZED CALCIUM PHOSPHATE CEMENTS WITH ENHANCED CELL FUNCTIONS FOR BONE REPAIR

The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same. 1. A bone paste comprising calcium phosphate cement and one or more biofunctional agents , wherein the biofunctional agents are selected from the group consisting of RGD-containing peptides , fibronectin , fibronectin-like engineered polymer protein (FEPP) , derived extracellular matrix (dECM) , and platelet concentrate.2. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and an RGD-containing peptide claim 1 , wherein RGD-containing peptide is selected from the group consisting of RGD claim 1 , G4RGDSP claim 1 , RGDS claim 1 , GRGD claim 1 , GRGDGY claim 1 , RGDSGGC claim 1 , and GRGDS claim 1 , and wherein RGD-containing peptide is present within a range of about 0.0005% to about 5% by mass.3. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and fibronectin claim 1 , wherein fibronectin is present within a range of about 0.0005% to about 5% by mass.4. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and FEPP claim 1 , wherein FEPP is present within a range of about 0.0005% to about 5% by mass.5. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and dECM claim 1 , wherein dECM is present within a range of about 0.001% to about 10% by mass.6. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and platelet concentrate claim 1 , wherein platelet concentrate is present within a range of about 0.001% to about 10% by mass.7. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and any two of the biofunctional agents.8. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and any three of the biofunctional agents.9. The bone paste of claim 1 , wherein the ...

BONE CEMENT AND METHODS OF USE THEREOF

A bone cement comprising an acrylic polymer mixture which is formulated to have a relatively high viscosity for a relatively long window, due to distributions of molecular weights and/or sizes of acrylic beads. 1. A bone cement comprising an acrylic polymer mixture , the cement characterized in that it achieves a viscosity of at least 500 Pascal-second within 180 seconds following initiation of mixing of a monomer component and a polymer component and characterized by sufficient biocompatibility to permit in-vivo use.2. A bone cement according to claim 1 , wherein the viscosity of the mixture remains between 500 and 2000 Pascal-second for a working window of at least 5 minutes after the initial period.3. A bone cement according to claim 2 , wherein the working window is at least 8 minutes long.4. A bone cement according to claim 1 , wherein the mixture includes PMMA.5. A bone cement according to claim 1 , wherein the mixture includes Barium Sulfate.6. A bone cement according to claim 4 , wherein the PMMA is provided as a PMMA/styrene copolymer.7. A bone cement according to claim 4 , wherein the PMMA is provided as a population of beads divided into at least two sub-populations claim 4 , each sub-population characterized by an average molecular weight.8. A bone cement according to claim 7 , wherein a largest sub-population of PMMA beads is characterized by an MW of 150 claim 7 ,000 Dalton to 300 claim 7 ,000 Dalton.9. A bone cement according to claim 7 , wherein a largest sub-population of PMMA beads includes 90-98% (w/w) of the beads.10. A bone cement according to claim 7 , wherein a high molecular weight sub-population of PMMA beads is characterized by an average MW of at least 3 claim 7 ,000 claim 7 ,000 Dalton.11. A bone cement according to claim 7 , wherein a high molecular weight sub-population of PMMA beads includes 2 to 3% (w/w) of the beads.12. A bone cement according to claim 7 , wherein a low molecular weight sub-population of PMMA beads is characterized ...

MINIMALLY INVASIVE TREATMENT OF VERTEBRA (MITV) USING A CALCIUM PHOSPHATE COMBINATION BONE CEMENT

Featured are a biocompatible, injectable, self-setting, cohesive, bone-bonding and remodeling calcium phosphate composite material and its use in methods of repairing defective bone, e.g., in vertebroplasty augmentation and kyphoplasty. 1. A method for performing vertebroplasty on a vertebral body comprising:a) injecting a flowable bone cement into at least one said vertebral body, said flowable bone cement comprising a nanocrystalline apatitic calcium phosphate, a radio-opaque agent, and a pharmaceutically acceptable fluid in an amount sufficient to produce said flowable bone cement; andb) allowing said flowable bone cement to harden, wherein said flowable bone cement, when hardened, has a compressive strength of 1 mPa or greater and is resorbable in vivo.2. The method of claim 1 , wherein said flowable bone cement further comprises at least one agent that promotes bone growth or inhibits bone resorption.3. The method of claim 1 , wherein the flowable bone cement further comprises demineralized bone matrix.4. The method of claim 1 , wherein the pharmaceutically acceptable fluid is selected from water claim 1 , saline claim 1 , a phosphate buffer claim 1 , a biological fluid claim 1 , in particular claim 1 , blood or a fluid that includes blood components claim 1 , and glycerol.5. The method of claim 1 , wherein said vertebral body is in a non-human mammal.6. The method of claim 1 , wherein said vertebral body is in a human.7. The method of further comprising injecting said flowable bone cement into two or more vertebral bodies.8. The method of claim 1 , wherein said vertebral body comprises fractured or osteoporotic bone.9. The method of claim 1 , wherein said nanocrystalline apatitic calcium phosphate comprises crystals within the range of 30-80 nm.10. The method of claim 9 , wherein said nanocrystalline apatitic calcium phosphate comprises crystals within the range of 30-50 nm.11. The method of claim 1 , wherein said nanocrystalline apatitic calcium phosphate has ...

Pressure Sensitive Adhesive Compositions Containing Plant and Animal Butters

The present invention relates to an adhesive composition applicable to skin comprising a shea butter and /or at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device and cosmetic adhesive applications including such adhesive composition. 1. A pressure sensitive adhesive composition comprising:a. 2 to 45% by weight of a homopolymer or copolymer selected from the group consisting of polyisobutylene, ethylene vinyl acetate, ethylene vinyl acetate carbon monoxide, ethylene butyl acetate, ethylene vinyl alcohol, ethylene butyl acrylate, ethylene butyl acrylate carbon monoxide, polystyrene copolymers and mixtures thereof;b. 1 to 10% by weight of a butter selected from the group consisting of shea, avocado, orange peel, aloe or animal derived butter and mixtures thereof; andc. 15- 45% by weight of a tackifier selected from the group consisting of natural rosin, modified rosin, glycerol ester of natural rosin, glycerol-ester of modified rosin, pentaerythritol ester of natural rosin, pentaerythritol ester of modified rosin, phenolic modified terpene resin, aliphatic petroleum hydrocarbon resin, cycloaliphatic resin and mixtures thereof.2. A pressure sensitive adhesive composition according to wherein said butter is shea butter. This application claims the benefit of U.S. Ser. No. 61/694,738 filed on Aug. 29, 2012.The present invention relates to a pressure sensitive, moldable adhesive dressing composition suitable for various medical device applications, particularly ostomy care applications to prevent leakage around the stoma which can lead to damage of healthy neighboring skin. Furthermore, the adhesive dressing composition can be molded to maximize coverage and protection of various abdominal anatomies, sealing the area between the skin and ostomy appliance. In particular, the present invention relates to a pressure sensitive adhesive composition comprising polyethylene copolymers, polystyrene copolymers, poly-isobutylene ...

Surgical Adhesive Including Honey and Methods of Preparation and Use Thereof

A mixture of honey solution and a surgical adhesive, typically a cyanoacrylate adhesive is described. The adhesive and honey solution are mixed and applied to a cut or wound prior to the cure of the mixture. The adhesive mixture, which retains the strength of the unadulterated adhesive significantly reduces the growth of bacteria in the vicinity of the associated closed cut or wound, has applicability in both human and veterinary medicine. 1. A mixture comprising a cyanoacrylate adhesive and honey solution.2. The mixture of claim 1 , wherein the adhesive is a n-Butyl-2 Cyanoacrylate adhesive.3. The mixture of claim 1 , wherein honey in the honey solution is a Manuka Honey.4. The mixture of claim 1 , wherein honey in the honey solution has a Kfactor of at least 10.5. The mixture of claim 1 , wherein honey in the honey solution has a Kfactor of at least 15.6. The mixture of claim 1 , wherein the honey solution comprises two thirds honey to one third water by weight.7. The mixture of claim 1 , wherein the ratio of honey solution to adhesive by volume is between 20:80 and 80:20.8. A combination comprising packaging claim 1 , honey solution claim 1 , and cyanoacrylate adhesive claim 1 , wherein the packaging includes (a) a first sealed chamber containing the honey solution and (b) a second sealed chamber containing cyanoacrylate adhesive claim 1 , the two chambers being distinct and not in fluid communication with each other.9. The combination of claim 8 , wherein the packaging comprises a dual chamber syringe claim 8 , wherein each chamber includes a plunger end and a dispensing end.10. The combination of claim 8 , wherein the packaging a flexible packet.11. The combination of claim 9 , further comprising a mixing nozzle claim 9 , the mixing nozzle adapted to operatively couple to the dispensing end of each of the first and second chambers.12. The combination of claim 10 , wherein the packet further includes a tear-off or cut-off end to provide access to the first and ...

ADHESIVE COMPOSITIONS AND PATCHES, AND ASSOCIATED SYSTEMS, KITS, AND METHODS

Adhesive compositions and patches, and associated systems, kits, and methods, are generally described. Certain of the adhesive compositions and patches can be used to treat tissues (e.g., in hemostatic or other tissue treatment applications), according to certain embodiments. 1. A water-activated adhesive article , comprising:a substrate; anda water activated polymeric adhesive disposed within a solvent and in contact with the substrate.2. The water-activated adhesive article of claim 1 , wherein the substrate is biodegradable.3. The water-activated adhesive article of any one of - claim 1 , wherein the substrate has a moisture content of less than about 20 wt %.4. The water-activated adhesive article of any one of - claim 1 , wherein the substrate has a water content of less than about 20 wt %.5. The water-activated adhesive article of any one of - claim 1 , wherein the substrate comprises a polymer.6. The water-activated adhesive article of any one of - claim 1 , wherein the substrate comprises a biopolymer.7. The water-activated adhesive article of any one of - claim 1 , wherein the substrate comprises a protein and/or a polysaccharide.8. The water-activated adhesive article of any one of - claim 1 , wherein the substrate comprises fibrin claim 1 , collagen claim 1 , cellulose claim 1 , starch claim 1 , chitosan claim 1 , hyaluronic acid claim 1 , polylactic acid claim 1 , polyglycolic acid and/or tissue-based materials.9. The water-activated adhesive article of any one of - claim 1 , wherein the substrate comprises fibrin.10. The water-activated adhesive article of any one of - claim 1 , wherein the substrate comprises a synthetic polymer.11. The water-activated adhesive article of any one of - claim 1 , wherein the substrate is substantially free of thrombin.12. The water-activated adhesive article of any one of - claim 1 , wherein the water-activated polymeric adhesive comprises the adhesive composition of any one of -.13. The water-activated adhesive article ...

Biocompatible Adhesive Materials and Methods

Biocompatible adhesive materials, such as for use with biological tissues and/or medical implants, are provided, as well as methods and kits for making and using the biocompatible adhesive materials. The biocompatible adhesive materials include a dendrimer component and a polymer component, and may be tailored for specific tissue types and conditions. 1. A kit for making an adhesive comprising:a first part which includes a first solution comprising a polymer component, wherein the polymer component comprises a polymer having one or more aldehyde groups; anda second part which includes a second solution comprising a dendrimer component, wherein the dendrimer component comprises a dendrimer having at least 2 branches with one or more surface groups, wherein less than 75% of the surface groups comprise at least one primary or secondary amine.2. The kit of claim 1 , further comprising a syringe claim 1 , wherein the first and second solutions are stored in the syringe.3. The kit of claim 2 , wherein the syringe comprises separate reservoirs for the first solution and second solution.4. The kit of claim 3 , wherein the syringe comprises a mixing tip.5. The kit of claim 1 , further comprising at least two reservoirs with different concentrations of the first solution.6. The kit of claim 1 , further comprising at least two reservoirs with different concentrations of the second solution.7. The kit of claim 1 , further comprising instructions for selecting an appropriate concentration of at least one of the first solution or second solution to compensate for the characteristics of one or more biological tissues.8. The kit of claim 1 , wherein the dendrimer component claim 1 , polymer component claim 1 , or both components claim 1 , comprise a drug.9. The kit of claim 1 , wherein the dendrimer component claim 1 , polymer component claim 1 , or both components claim 1 , comprise stem cells or other cells.10. A drug delivery composition comprising:a polymer component, wherein ...

Calcium phosphate cement compositions that set into high strength porous structures

Calcium phosphate cement compositions are provided. Aspects of the cement compositions include a dry reactant component comprising a reactive α-tricalcium phosphate component, a multi-size pore forming calcium sulphate dihydrate component and a demineralized bone matrix component. During use, the dry reactant is combined with a setting fluid to produce a sellable composition that sets into a high strength porous product. Aspects of the invention further include the settable compositions themselves as well as kits for preparing the same. Methods and compositions as described herein find use in a variety of applications, including hard tissue repair applications.

THERAPEUTIC COMPOSITIONS

A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, , and cells harvested with the amniotic fluid. 1. A therapeutic composition , comprising:{'i': 'vernix', 'an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid (HA), or both, said composition being substantially free of lanugo, , and cells harvested with the amniotic fluid.'}2. The composition of claim 1 , wherein the composition has less than or equal to 10 claim 1 ,000 particles per milliliter of particles having a particle size of 10 microns or greater.3. The composition of claim 1 , wherein the composition has less than or equal to 300 particles per milliliter of particles having a particle size of 25 microns or greater.4. The composition of claim 1 , wherein the therapeutic proteins are present in the composition in an amount of from 0.15 mg/ml to 10 mg/ml.5. The composition of claim 1 , wherein the composition has an optical density of less than 0.20 when exposed to electromagnetic radiation at a wavelength of 590 nm.6. The composition of claim 1 , further comprising hemoglobin in an amount from 1 μg/ml to 60 μg/ml7. The composition of claim 1 , wherein the composition is a lyophilized amniotic fluid composition.8. The composition of claim 1 , further comprising an active agent.9. The composition of claim 8 , wherein the active agent is a member of the group consisting of an anti-infective agent claim 8 , an antibiotic claim 8 , an anti-tumor agent claim 8 , an anti-inflammatory agent claim 8 , a pain-controlling agent claim 8 , an anti-rheumatic agent claim 8 , a bisphosphonate claim 8 , a supplementary growth factor claim 8 , a supplementary cytokine claim 8 , an amino acid claim 8 , a protein claim 8 , a vaccine claim 8 , a hormone claim 8 , a vitamin claim 8 , a phytoestrogen ...

Method of Hemostasis

A method of hemostasis includes the step of applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has (a) a weight average molecular weight of from 10,000 to 50,000, (b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and (c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and a second agent including a crosslinking agent for the gelatin derivative. 1. A method of hemostasis , comprising the step of: [ (a) a weight average molecular weight of from 10,000 to 50,000,', '(b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and', '(c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and, 'a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has'}, 'a second agent comprising a crosslinking agent for the gelatin derivative., 'applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of'}2. The method of hemostasis according to claim 1 , wherein the first agent is applied in the form of an aqueous solution having a pH of from 8 to 11 claim 1 , and the second agent is applied in the form of an aqueous solution having a pH of from 3 to 8.3. The method of hemostasis according to claim 2 , wherein the first agent and the second agent are applied by using a dual syringe dispenser.4. The method of hemostasis according to claim 1 , wherein the gelatin is Alaska pollock-derived gelatin.5. The method of hemostasis according to claim 1 , wherein the crosslinking agent is pentaerythritol polyethylene glycol ether tetrasuccinimidyl glutarate having a weight average molecular weight of from 3 claim 1 ,000 to 30 claim 1 ,000.6. ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A system for preparing a cell preparation , comprising: an anticoagulant;', 'a cap sealing the anticoagulant in the tube;, 'a tube havingthe tube adapted to centrifuge blood to form a platelet rich plasma;a container having hyaluronic acid;an applicator device adapted to administer to a patient a cell preparation including a mixture of the platelet rich plasma and the hyaluronic acid.2. The system of claim 1 , further comprising a thixotropic gel sealed in the tube claim 1 , the thixotropic gel separating the blood by forming a barrier between the platelet rich plasma and red blood cells when the tube is centrifuged for a length of time.3. The system of claim 2 , wherein:the thixotropic gel includes a polymer mixture;the anticoagulant includes a buffered sodium citrate solution at approximately 0.1 M.4. The system of claim 1 , wherein the applicator device comprises a double syringe mixing the platelet rich plasma and hyaluronic acid to form the cell preparation at a treatment site of the patient.5. The system of claim 1 , wherein the platelet rich plasma and the hyaluronic acid are mixed in the container.6. The system of claim 1 , wherein the container and the applicator device comprise the same device.7. The system of claim 1 , further comprising:phlebotomy accessories including a needle for drawing the blood from a patient;wherein the tube is sealed with the cap under vacuum pressure, the vacuum pressure helping to aspirate the blood from ...

RADIOACTIVE LIQUID EMBOLIC

Liquid embolic preparations and medical treatment methods of using those preparations are described. In some embodiments, the preparations or solutions can transition from a liquid to a solid for use in the embolization. The preparations can include biocompatible polymers with covalently bound radioactive iodine isotopes. 1. A polymeric composition comprising:a biocompatible polymer comprising a reaction product of:a first monomer including a polymerizable moiety having a biodegradable linkage to a visualization agent having at least one aromatic ring, wherein the at least one aromatic ring includes at least one iodine atom, wherein at least one of the at least one iodine atom is a radioactive isotope,and a second monomer including a polymerizable moiety and at least one hydroxyl group; anda non-physiological solution;wherein the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution.2. The polymeric composition of claim 1 , wherein the biodegradable linkage is SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO:5 claim 1 , SEQ ID NO:6 claim 1 , SEQ ID NO:7 claim 1 , SEQ ID NO:8 claim 1 , SEQ ID NO:9 claim 1 , SEQ ID NO:10 claim 1 , SEQ ID NO:11 claim 1 , or SEQ ID NO:12.3. The polymeric composition of claim 1 , wherein the polymeric composition is covalently functionalized with folic acid or a functionalized folic acid.4. The polymeric composition of claim 1 , wherein the radioactive isotope is I claim 1 , I claim 1 , I claim 1 , I claim 1 , or a combination thereof.5. The polymeric composition of claim 1 , wherein the radioactive isotope is I.6. The polymeric composition of claim 1 , wherein the radioactive isotope is I.7. The polymeric composition of claim 1 , wherein the radioactive isotope is I.8. The polymeric composition of claim 1 , wherein the radioactive isotope is I.9. The polymeric composition of claim 1 , wherein the first monomer is ...

Antimicrobial medical biomaterial and a method for preparing the same

An antibacterial medical biomaterial includes an acellular small intestinal submucosal matrix material, an antibacterial gel layer located on a surface of the acellular small intestinal submucosal matrix material, and an absorbable fiber layer located on a surface of the antibacterial gel layer. Sulfadiazine silver is on the surface of the acellular small intestinal submucosal matrix material and/or within the acellular small intestinal submucosal matrix material. An absorbable fiber layer to which the sulfadiazine silver is attached, wherein the content of sulfadiazine silver in the absorbable fiber is 1 wt. %˜2 wt. %. The medical biomaterial is usable as an external medicine for treating wound infections relayed by burns or wounds, and for reducing the incidence of infection by using a conventional central venous catheter with a sulfadiazine silver antibacterial coating, so that the medical biomaterial loaded with sulfadiazine silver also has antibacterial activity consistent with sulfadiazine silver.

Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

ELECTROMAGNETIC-WAVE TREATMENT DEVICE

The shoulder stiffness, the muscle fatigue, etc., are easily and efficiently improved by the electromagnetic waves without the usage of the power supplies and the large treatment tools. The electromagnetic-wave treatment device has an antenna acupuncture needle and a fixing member . The antenna acupuncture needle has a sharp end portion having one end portion formed into a needle shape. The fixing member is fixed to the antenna acupuncture needle . This antenna acupuncture needle is fixed so that the sharp end portion of the antenna acupuncture needle protrudes from the fixing member . And, the antenna acupuncture needle functions as an antenna receiving the electromagnetic waves in a space. 1. An electromagnetic-wave treatment device comprising:an acupuncture needle portion having one end portion formed into a needle shape; anda fixing member configured to fix the acupuncture needle portion,wherein the acupuncture needle portion is fixed so that the needle-shaped one end portion of the acupuncture needle portion protrudes from the fixing member, andthe acupuncture needle portion functions as an antenna receiving electromagnetic waves in a space.2. The electromagnetic-wave treatment device according to claim 1 , further comprisingan adhesive tape configured to paste the fixing member to skin,wherein the fixing member is formed on a surface facing an adhesive surface of the adhesive tape, andthe needle-shaped one end portion of the acupuncture needle portion protrudes from the adhesive surface of the adhesive tape.3. The electromagnetic-wave treatment device according to claim 1 ,wherein the acupuncture needle portion receives electromagnetic waves in a frequency band used for mobile phone communication.4. The electromagnetic-wave treatment device according to claim 1 ,wherein the fixing member is made of metallic adhesive resin.5. The electromagnetic-wave treatment device according to claim 1 ,wherein the acupuncture needle portion has a radial functioning as a ...

MEDICAL SEALANT GLUE CAPABLE OF PROMOTING WOUND HEALING AND PREPARATION METHOD THEREOF

The disclosure provides a medical sealant glue capable of promoting wound healing and a preparation method thereof. The medical sealant glue is formed by covalent cross-linking of two components after being physically mixed by a mixing tool, wherein the first component is a nucleophilic component, and the second component is an electrophilic component. The medical sealant glue has a gelation time of 1-10 s, a swelling ratio of 0-100%, a bursting strength of 100-250 mmHg, and a degradation time of 0.5-300 days. The nucleophilic component of the medical sealant glue contains exosome or hyaluronic acid and chitosan, and thus the medical sealant glue not only has the effect of promoting wound healing, but also has antibacterial and anti-infection effects. 1. A medical sealant glue capable of promoting wound healing , wherein: raw materials for preparing the medical sealant glue comprise a first component containing nucleophilic functional groups and a second component containing electrophilic functional groups , wherein the first component is composed of dendritic molecules , exosome or hyaluronic acid and chitosan , and the second component is active polyethylene glycol.2. The medical sealant glue capable of promoting wound healing according to claim 1 , wherein: the dendritic molecules are one or more of dendritic polyethylene imine claim 1 , dendritic polypropylene imine claim 1 , dendritic poly-L-lysine and dendritic polyamide.3. The medical sealant glue capable of promoting wound healing according to claim 1 , wherein: the exosome is exosome secreted from one or several of adipose-derived mesenchymal stem cells claim 1 , placenta-derived mesenchymal stem cells and bone marrow mesenchymal stem cells.4. The medical sealant glue capable of promoting wound healing according to claim 1 , wherein: the chitosan is one or more of chitosan hydrochloride claim 1 , chitosan acetate and chitosan lactate.5. The medical sealant glue capable of promoting wound healing according ...

THERAPEUTIC COMPOSITIONS

A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid. 1. A method of treating a subject with an adverse health condition responsive to treatment with an amniotic fluid agent , comprising:administering a therapeutically effective amount of a composition comprising a processed amniotic fluid to the subject.2. The method of claim 1 , wherein the adverse health condition is a member selected from the group consisting of: a wound claim 1 , a respiratory condition claim 1 , an inflammatory condition claim 1 , chronic pain claim 1 , a urological condition claim 1 , arthritis claim 1 , a skeletal condition claim 1 , an ophthalmic condition claim 1 , a cardiovascular condition claim 1 , a neurological condition claim 1 , a digestive condition claim 1 , a reproductive condition claim 1 , a cosmetic condition claim 1 , or combinations thereof3. The method of claim 2 , wherein the adverse health condition is a cardiovascular condition.4. The method of claim 3 , wherein the cardiovascular condition is a member selected from the group consisting of: aneurysm claim 3 , atherosclerosis claim 3 , high blood pressure claim 3 , peripheral arterial disease claim 3 , angina claim 3 , coronary artery disease claim 3 , coronary heart disease claim 3 , heart attack claim 3 , heart failure claim 3 , stroke claim 3 , transient ischemic attacks claim 3 , pericardial disease claim 3 , heart valve disease claim 3 , congenital heart disease claim 3 , cardiomyopathy claim 3 , pericardial disease claim 3 , aorta disease claim 3 , Marfan syndrome claim 3 , vascular disease claim 3 , rheumatic heart disease claim 3 , or combinations thereof5. The method of claim 4 , wherein the cardiovascular condition is a heart attack.6. The method of claim 1 , wherein administration is ...

Novel manufacturing and applications of adhesive materials

A novel method of manufacturing and applications of a composition of matter comprising of a cross-linked form of a polysaccharide, at least one cross-linking agent comprised of divalent ions for effecting said cross-linked form of said polysaccharide, and at least one synthetically prepared phloroglucinol compound selected from the group comprising of phloroglucinol, a derivative of phloroglucinol, and a polymer synthetically prepared from phloroglucinol or a derivative of phloroglucinol, as an adhesive in procedures for reattaching or repairing body parts or components thereof, such as tissue, of (human or animal) subjects, especially under wet conditions, for example, involving adhesion of wet surfaces.

Methods for adhering tissue surfaces and materials and biomedical uses thereof

The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.

PULVERULENT SEMISYNTHETIC MATERIAL OBTAINED BY MODIFYING THE COMPOSITION OF A NATURAL MARINE BIOMATERIAL, METHOD OF MANUFACTURE THEREOF, AND APPLICATIONS THEREOF

A pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from Pinctadines, notably , and , notably , in pulverulent form, with the addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation. 1. Pulverulent semisynthetic material , derived from a natural marine biomaterial , with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation.2Tridacnes. Pulverulent semisynthetic material according to claim 1 , wherein the natural marine biomaterial is the aragonitic inner layer of the shell of bivalve molluscs selected from the group comprising Pinctadines and claim 1 , said aragonitic layer being in pulverulent form.3. Pulverulent semisynthetic material according to claim 2 , wherein the natural biomaterial in pulverulent form has a granulometry from 5 nm to 100 μm.4Tridacnes.. Pulverulent semisynthetic material according to claim 1 , wherein the insoluble and soluble biopolymers are extracted from the aragonitic inner layer and/or from the calcitic outer layer of the shell of the bivalve molluscs selected from the group comprising Pinctadines and5. Pulverulent semisynthetic material according to claim 1 , wherein the calcium carbonate transformed by carbonation is derived from a natural terrestrial claim 1 , natural marine or precipitated calcium carbonate claim 1 , or from the inorganic fraction of the aragonitic layer after extraction of the insoluble and soluble biopolymers.6. Pulverulent semisynthetic material according to claim 1 , wherein said pulverulent semisynthetic material is bioabsorbable.7Pinctada maximaPinctada margaritifera.. Pulverulent semisynthetic material according to claim 2 , wherein the Pinctadines are selected from the group comprising and8TridacnesTridacna gigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopusHippopus porcelanus.. Pulverulent semisynthetic ...

DEVICES HAVING A LASER FOR CLOSING OPEN WOUNDS AND FOR PROCESSING TISSUE OF A HUMAN OR ANIMAL BODY

The present invention relates to a device for closing an open, bleeding wound of an animal or human body. The invention further relates to a device for processing tissue of a human or animal body, for example, a device for producing a support in a vessel of the body. The device for closing a bleeding wound firstly comprises a laser for irradiating the blood in the wound with infrared laser radiation. According to the invention, the laser radiation of the laser can be adjusted such that two- or multiphoton absorption occurs in irradiated regions of the blood, whereby the blood in the irradiated regions polymerises into a solidified biopolymer and closes the wound. 1. A device for closing a bleeding wound of an animal or human body , comprising:a laser for irradiating the blood in the wound with infrared laser radiation,wherein the infrared laser radiation of the laser may be adjusted so that a two- or multi-photon absorption takes place in the irradiated regions of the blood, as a result of which the blood in the irradiated regions polymerizes into a solidified biopolymer and closes the wound.2. The device according to claim 1 , further comprising an applicator device for applying a cell adhesive fluid in the open wound.3. The device according to claim 1 , wherein the infrared laser radiation of the laser may be adjusted so that a two- or multi-photon absorption takes place in the irradiated regions of the blood claim 1 , as a result of which the blood in the irradiated regions polymerizes with no denaturing to form a solidified biopolymer and closes the wound.4. A device for processing tissue of a human or animal body claim 1 , comprising:an applicator device for applying a cell adhesive fluid to the tissue to be processed; anda laser for irradiating the applied cell adhesive fluid with infrared laser radiation, wherein the infrared laser radiation of the laser may be adjusted so that a two- or multi-photon absorption takes place in the irradiated regions of the ...

Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, said endoscopic procedure preferably comprising the administration of said pharmaceutical composition to a human. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human.

Methods and materials for treating tumors

This document provides methods and materials for treating a mammal (e.g., a human) having one or more tumors. For example, embolic agents including an amnion tissue preparation (e.g., amnion coated embolic agents) that can be used in arterial embolization to reduce or eliminate blood flow in a blood vessel that supplies a tumor are provided.

MINIMALLY INVASIVE TREATMENT OF VERTEBRA (MITV) USING A CALCIUM PHOSPHATE COMBINATION BONE CEMENT

Featured are a biocompatible, injectable, self-setting, cohesive, bone-bonding and remodeling calcium phosphate composite material and its use in methods of repairing defective bone, e.g., in vertebroplasty augmentation and kyphoplasty. 1. A method for performing vertebroplasty on a vertebral body comprising:a) injecting a flowable bone cement into at least one said vertebral body, said flowable bone cement comprising a nanocrystalline apatitic calcium phosphate, a radio-opaque agent, carboxymethyl cellulose in an amount of 10% or less by weight, and a pharmaceutically acceptable fluid in an amount sufficient to produce said flowable bone cement; andb) allowing said flowable bone cement to harden, wherein said flowable bone cement, when hardened, has a compressive strength of 1 mPa or greater and is resorbable in vivo.2. The method of claim 1 , wherein said flowable bone cement further comprises:a) at least one agent that promotes bone growth or inhibits bone resorption;b) one or more crystal growth inhibitors;c) demineralized bone matrix;d) benzoyl peroxide powder;e) hydroxyethyl methacrylate (HEMA);f) a cohesiveness agent, an osteopenic agent, or a medicinal agent; orq) a biologically active agent.3. (canceled)4. The method of claim 1 , wherein the pharmaceutically acceptable fluid is selected from water claim 1 , saline claim 1 , a phosphate buffer claim 1 , a biological fluid claim 1 , in particular claim 1 , blood or a fluid that includes blood components claim 1 , and glycerol.5. The method of claim 1 , wherein said vertebral body:a) is in a human or non-human mammal; orb) comprises fractured or osteoporotic bone.6. (canceled)7. The method of further comprising:a) injecting said flowable bone cement into two or more vertebral bodies; orb) creating a cavity in said vertebral body and injecting said flowable bone cement into said cavity.8. (canceled)9. The method of claim 1 , wherein said nanocrystalline apatitic calcium phosphate comprises crystals within the ...

New A-PRP Medical Device & Tissue Engineering Composition, Manufacturing Machines And Process

The present invention is related to the field of tissue regeneration. It concerns more particularly new manufacturing machines and processes, new A-PRP or PRP, hyaluronic acid and/or chitosan compositions, used alone or in combination, and related devices. 1. A system for preparing a cell composition , comprising: an anticoagulant;', 'a cell selector gel including a polymer, the cell selector gel adapted to separate the blood by forming a barrier between the platelet rich plasma and red blood cells when the tube is centrifuged for a length of time;', a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa;', 'a hyaluronic acid of approximately 4000 KDa or above 4000 KDa;', 'a hyaluronic acid of approximately 600 KDa or less than 600 KDa;, 'at least one hyaluronic acid selected from the following], 'a tube adapted to centrifuge a blood to separate a platelet rich plasma, the tube havingthe at least one hyaluronic acid mixing with the platelet rich plasma to form the cell composition.2. The system of claim 1 , wherein the at least one hyaluronic acid is selected from the following:a hyaluronic acid of approximately 1000 KDa to approximately 2000 KDa;a hyaluronic acid of approximately 600 KDa or less than 600 KDa.3. The system of claim 1 , wherein the at least one hyaluronic acid is at a concentration of approximately 1.5% to approximately 2.5%.4. The system of claim 1 , wherein the at least one hyaluronic acid comprises a hyaluronic acid of approximately 1400 KDa to approximately 1600 KDa.5. The system of claim 1 , wherein the at least one hyaluronic acid comprises:at least one low molecular weight hyaluronic acid that is approximately 600 KDa or less than 600 KDa; andat least one high molecular weight hyaluronic acid that is approximately 4000 KDa or above 4000 KDa.6. The system of wherein:a ratio of the low molecular weight hyaluronic acid to the high molecular weight hyaluronic acid is approximately 2:3 and a total concentration of hyaluronic acid is ...

PRODUCTS AND DEVICES FOR CONTROLLING AND STOPPING BLEEDING AND METHODS OF USING

Systems, devices, compositions, and methods for treating bleeding, for containing blood that has been lost by a subject due to bleeding, and for treating surfaces contaminated with blood or expected to be contaminated with blood are disclosed. The systems, devices, compositions, and methods utilize platelets, platelet-derived materials, or both. The invention includes sprayers, nebulizers, and equivalents, to deliver platelets and/or platelet-derived materials to desired surfaces. Exemplary embodiments include the use of a pressurized sprayer configured to deliver a topical administration of a lyophilized platelet and/or platelet-derived material to a surface. 1. A system for applying platelets or platelet-derived material to a surface , said system comprising a device comprising , in physical and fluid connection , at least one pressure delivery unit , at least one composition container , and at least two application units;wherein the composition container contains a composition comprising the platelets or platelet-derived material, andwherein the at least two application units each contain at least one nozzle, forming an array or nozzle bank.2. The system of claim 1 , wherein the pressure delivery unit delivers pressure by way of a pneumatic pump.3. The system of claim 1 , wherein the pressure delivery unit delivers pressure by way of a gas or liquid propellant.4. The system of claim 1 , wherein the pressure delivery unit delivers pressure by way of compressive force supplied by a human.5. The system of claim 1 , wherein the composition comprises lyophilized platelets.6. The system of claim 5 , wherein the lyophilized platelets are in a dry state.7. The system of claim 5 , wherein the lyophilized platelets are in a rehydrated state claim 5 , and wherein the composition further comprises platelet-derived material.8. The system of claim 1 , wherein the composition comprises one or more therapeutic agents claim 1 , one or more disinfectants claim 1 , or both.9. The ...

BONE PASTES COMPRISING BIOFUNCTIONALIZED CALCIUM PHOSPHATE CEMENTS WITH ENHANCED CELL FUNCTIONS FOR BONE REPAIR

The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same. 1. A bone paste comprising calcium phosphate cement and one or more biofunctional agents , wherein the biofunctional agents are selected from the group consisting of RGD-containing peptides , fibronectin , fibronectin-like engineered polymer protein (FEPP) , derived extracellular matrix (dECM) , and platelet concentrate.2. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and an RGD-containing peptide claim 1 , wherein RGD-containing peptide is selected from the group consisting of RGD claim 1 , G4RGDSP claim 1 , RGDS claim 1 , GRGD claim 1 , GRGDGY claim 1 , RGDSGGC claim 1 , and GRGDS claim 1 , and wherein RGD-containing peptide is present within a range of about 0.0005% to about 5% by mass.3. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and fibronectin claim 1 , wherein fibronectin is present within a range of about 0.0005% to about 5% by mass.4. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and FEPP claim 1 , wherein FEPP is present within a range of about 0.0005% to about 5% by mass.5. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and dECM claim 1 , wherein dECM is present within a range of about 0.001% to about 10% by mass.6. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and platelet concentrate claim 1 , wherein platelet concentrate is present within a range of about 0.001% to about 10% by mass.7. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and any two of the biofunctional agents.8. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and any three of the biofunctional agents.9. The bone paste of claim 1 , wherein the ...

SURGICAL SEALANT

A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH—CHRR, wherein “Gltn” represents a gelatin residue, Ris the hydrophobic group, and Ris a hydrogen atom or the hydrophobic group; and (2) a second agent comprising a crosslinking agent for the gelatin derivative. 1. A surgical sealant consisting of (a) has a weight average molecular weight of from 10,000 to 50,000;', '(b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms;', '(c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and', {'br': None, 'sup': 1', '2, 'GltnNH—CHRR'}, '(d) comprises a structure represented by the following formula, {'sup': 1', '2, 'wherein “Gltn” represents a gelatin residue, Ris the hydrophobic group, and Ris a hydrogen atom or the hydrophobic group; and'}], '(1) a first agent comprising a gelatin derivative, wherein the gelatin derivative'}(2) a second agent comprising a crosslinking agent for the gelatin derivative, wherein said surgical sealant is resistant to radiation sterilization.2. The surgical sealant according to claim 1 , wherein the gelatin originates from a cold-water fish.3. The surgical sealant according to claim 2 , wherein the cold-water fish is codfish.4. The surgical sealant according to claim 1 , wherein the crosslinking agent is a polyethylene glycol ether polybasic acid ester.5. The surgical sealant according to claim 1 , wherein the first agent and the second agent are provided in such an amount that a ratio claim 1 , (an equivalent amount of ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A system for preparing a cell preparation , comprising:a first container having a cap and containing an anticoagulant, said cap sealing said anticoagulant in said first container, wherein said first container is a tube adapted to centrifuge whole blood for a length of time to separate platelet rich plasma;a second container containing hyaluronic acid; andan applicator device adapted to administer to a patient a cell preparation formed by mixing said platelet rich plasma from said first container and said hyaluronic acid from said second container.2. The system of claim 1 , further comprising a separator gel sealed in said tube claim 1 , said separator gel forming a barrier between said platelet rich plasma and red blood cells when said tube is centrifuged for a length of time.3. The system of claim 1 , wherein said anticoagulant comprises a sodium citrate solution.4. The system of claim 1 , wherein said applicator device comprises a double syringe adapted to mix said platelet rich plasma and said hyaluronic acid to form said cell preparation at a treatment site of said patient.5. The system of claim 1 , wherein said system is adapted to permit mixing of said platelet rich plasma and said hyaluronic acid in said second container.6. The system of claim 1 , wherein said second container and said applicator device comprise the same device.7. The system of claim 1 , further comprising:phlebotomy accessories comprising a needle for drawing blood ...

PULVERULENT SEMISYNTHETIC MATERIAL OBTAINED BY MODIFYING THE COMPOSITION OF A NATURAL MARINE BIOMATERIAL, METHOD OF MANUFACTURE THEREOF, AND APPLICATIONS THEREOF

A pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from the group including Pinctadines, notably and Tridacnes, notably in pulverulent form, with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation; it also relates to the method of preparation thereof and to the uses thereof. 1. Pulverulent semisynthetic material , derived from a natural marine biomaterial , with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation.2Pinctada maxima, margaritifera,Tridacnagigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopushippopus, Hippopusporcelanus,. Semisynthetic material according to claim 1 , characterized in that the natural marine biomaterial is the aragonitic inner layer of the shell of bivalve molluscs selected from the group comprising Pinctadines claim 1 , notably and Tridacnes claim 1 , notably said aragonitic layer being in pulverulent form.3. Semisynthetic material according to claim 1 , characterized in that the natural biomaterial in pulverulent form has a granulometry from 5 nm to 100 μm claim 1 , preferably from 20 nm to 50 μm claim 1 , even more preferably from 50 nm to 20 μm.4Pinctadamaxima, margaritifera,Tridacnagigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopushippopus, Hippopusporcelanus.. Semisynthetic material according to claim 1 , characterized in that the insoluble and soluble biopolymers are extracted from the aragonitic inner layer and/or from the calcitic outer layer of the shell of the bivalve molluscs selected from the group comprising Pinctadines claim 1 , notably and Tridacnes claim 1 , notably5. Semisynthetic material according to claim 1 , characterized in that the calcium carbonate transformed by carbonation is derived from a natural terrestrial claim 1 , natural marine or precipitated calcium carbonate claim 1 , or from the inorganic fraction ...

Silk-Based Adhesives

In some embodiments, the present invention provides compositions including silk fibroin, at least one hydrophilic agent, and at least one catechol donating agent, wherein the at least one hydrophilic agent and at least one catechol donating agent are conjugated to the silk fibroin. According to various embodiments, at least a portion of the silk fibroin may be crosslinked. In some embodiments, the silk fibroin is at least 50% (e.g., 60%, 70%, 80%, 90%, 95% or more) crosslinked. In some embodiments, the present invention also provides methods for making such compositions.

METHODS AND COMPOSITIONS FOR ACHIEVING HEMOSTASIS AND STABLE BLOOD CLOT FORMATION

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject. 117.-. (canceled)18. A hemostatic hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an acetic acid solution prior to acrylation , the hydrogel composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after formation.1930.-. (canceled)31. The hemostatic hydrogel composition of claim 18 , wherein the hemostatic hydrogel composition further comprises a total amount of free aldehyde groups of from about 0.1 to about 0.7 moles aldehyde/mole oxidized dextran.32. The hemostatic hydrogel composition of claim 18 , wherein the hemostatic hydrogel composition further comprises a ratio of primary aldehydes in the oxidized dextran to the amines in the acrylated chitosan from about 1.0 to about 2.0 claim 18 , and/or a ratio of total aldehydes in the oxidized dextran to amines in the acrylated chitosan from about 1.5 to about 3.0.33. The hemostatic hydrogel composition of claim 18 , wherein the hemostatic hydrogel composition further ...

BIOACTIVE BONE GRAFT SUBSTITUTES

Provided are synthetic bone graft substitutes that include bioactive glass and a carrier. Synthetic bone graft substitutes may include bioactive glass, glycerol and polyethylene glycol. Also provided are bone graft substitutes that include collagen and bioactive glass particles. Example bone graft substitutes may include collagen and bioactive glass particles. Other example embodiments may include Type I Bovine Collagen, an angiogenic agent, such as hyaluronic acid, and bioactive glass. Further provided are methods that include administering the present bone graft substitutes to a mammal, e.g., by surgical insertion of the bone graft substitute into the mammal, either alone or in conjunction with one or more implant devices. Further provided are kits that include the present bone grafts. 1. A bone graft substitute comprising:about 71% or more by weight of bioactive glass;glycerol; andpolyethylene glycol.2. The bone graft substitute of claim 1 , comprising about 71% to about 75% by weight of 45S5 bioactive glass claim 1 , about 15% to about 19% by weight of glycerol claim 1 , and about 10% to about 14% by weight of polyethylene glycol.3. The bone graft substitute of claim 1 , comprising about 71% by weight of 45S5 bioactive glass claim 1 , about 17% by weight of glycerol claim 1 , and about 12% by weight of polyethylene glycol 2000.4. The bone graft substitute of claim 1 , wherein said bone graft is in the form of a soft moldable putty.5. An implant comprising the bone graft substitute of .6. A bone graft substitute comprising:less than about 67% by weight of bioactive glass,glycerol; andpolyethylene glycol.7. The bone graft substitute of claim 6 , comprising about 53% to about 57% by weight of 45S5 bioactive glass particles claim 6 , about 18% to about 22% by weight of glycerol claim 6 , and about 23% to about 27% by weight of polyethylene glycol.8. The bone graft substitute of claim 7 , comprising about 55% by weight of 45S5 bioactive glass claim 7 , about 20% by ...

PHOSPHOCALCIC CEMENT COMPOSITION COMPRISING BLOOD

A method for promoting spine fusion inside intersomatic cages, comprising placing a fusion cage between two vertebral bodies, and injecting a bone cement paste inside said fusion cage, said bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood. 1. A method for promoting spine fusion inside intersomatic cages , comprising the following steps:placing a fusion cage between two vertebral bodies, andinjecting a bone cement paste inside said fusion cage, said bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood.2. The method of claim 1 , wherein the liquid component is blood.3. The method of claim 1 , wherein the powder component further comprises at least one calcium phosphate compound other than α-TCP.4. The method of claim 3 , wherein the calcium phosphate compound is selected from the group consisting of hydroxyapatite (HA) claim 3 , amorphous calcium phosphate (ACP) claim 3 , monocalcium phosphate anhydrous (MCPA) claim 3 , monocalcium phosphate monohydrate (MCPM) claim 3 , dicalcium phosphate dihydrate (DCPD) claim 3 , dicalcium phosphate anhydrous (DCPA) claim 3 , precipitated or calcium-deficient apatite (CDA) claim 3 , β-tricalcium phosphate (β-TCP) claim 3 , tetracalcium phosphate (TTCP) claim 3 , and mixtures thereof.5. The method of claim 1 , wherein the powder component comprises:α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, andat least one calcium phosphate compound selected from the group consisting of: MCPM, DCPD, CDA, and mixtures thereof.6. The method of claim 1 , wherein the powder component comprises at least 70% by weight of α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm claim 1 , ...

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 130-. (canceled)31. A sterilized , vacuum-sealed separator tube for preparing a platelet concentrate from whole blood consisting essentially of:An inlet adapted to introduce whole blood;An anticoagulant;A thixotropic gel; andA cap configured to hermetically seal the separator tube,wherein the separator tube is adapted to be centrifuged in a single centrifugation to separate blood components in the whole blood into a platelet concentrate to be administered to a patient, and red blood cells,wherein the separator tube, anticoagulant, and thixotropic gel are sterilized together and hermetically sealed, andwherein the thixotropic gel is adapted to form a barrier between the platelet concentrate and red blood cells as a result of the centrifugation.32. The separator tube according to claim 31 , wherein the separator tube is adapted to be centrifuged at about 3 claim 31 ,800 RPM for about 3 to about 4 minutes to produce a platelet concentrate having a concentration of platelets of at least about 300 billion platelets per liter.33. The separator tube according to claim 31 , wherein the separator tube has a usable vacuum of from about 8 to about 10 mL.34. The separator tube according to claim 31 , wherein the cap is selected from a bromobutylene rubber stopper and a chlorobutylene rubber stopper.35. The separator tube according to claim 34 , wherein the cap further comprises a polyethylene cover.36. The separator tube according to claim 31 , wherein the ...

Use of photosynthetic scaffolds in tissue engineering

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

原料为娃娃鱼体表黏液的医用粘合剂及制备方法

原料为娃娃鱼体表黏液的医用粘合剂及制备方法，涉及医疗领域，所述的医用粘合剂是采用娃娃鱼的体表黏液为原料的。制备方法包括收下步骤：A、速冻；B、低温杀菌；C、低温粉碎；D、脱水；F、形成止血药粉。本发明利用娃娃鱼黏液的可以秒级止血粘合功能，实现对创口的快速止血、粘合；在整个的制备粘合剂的过程中，全部采用物理方法，因原料为纯天然的生物原料，无任何的毒副作用；所制备的粘合剂适用人群广，秒级止血粘合，效果佳，缓解了患者的痛苦，可广泛应用于外科手术、外伤创口愈合、美容等医疗领域。此外，对于成年娃娃鱼，每条每月可以获取体表黏液0.3‑0.6千克的黏液，而制备的医用粘合剂，可极大提高娃娃鱼养殖的附加值。

大鲵分泌物水凝胶及其制备方法和应用

本发明公开了一种大鲵分泌物水凝胶及其制备方法和应用，该方法通过将大鲵分泌物铺展开，并加水使得大鲵分泌物润湿，然后对润湿后的大鲵分泌物施加压力后能够形成水凝胶状的大鲵分泌物。上述大鲵分泌物水凝胶的制备方法操作简便，原料取材容易，制作成本较低。制备获得的大鲵分泌物水凝胶中分散性好、韧性和粘性较好，且所用的原料大鲵分泌物和水均为生物相容性极好的物质，植入体内后对体内的组织的刺激作用小。

Method and material for enhanced tissue-biomaterial integration

The present invention provides a composition and method for the covalent binding of a hydrogel to an extracellular matrix (ECM). Therapeutic applications include tissue repair and delivery of drugs or cells.

DEVICES AND METHODS FOR ENDOSCOPIC PATCH DELIVERY

Systems and methods of delivering a patch to a target site of a patient are described herein. The patch may comprise a biomaterial such as chitosan or extracellular matrix and may be biocompatible and/or bioresorbable. The system may include an endoscope, a patch, and one of an instrument or a cap, the patch being coupled to the respective instrument or cap and detachable therefrom. Methods of delivering the patch to the target site may include introducing an endoscope into a gastrointestinal tract of a patient, e.g., the patch being in a folded or crimped configuration, navigating a distal end of the endoscope proximate a target site; and applying the patch to the target site while releasing the patch from the endoscope. 120-. (canceled)21. A method of delivering a biocompatible patch to a target site of a patient , the method comprising:introducing a medical device into a gastrointestinal tract of the patient;positioning a distal end of the medical device proximate the target site; 'wherein the biocompatible patch is disposed on an outer surface of the instrument;', 'introducing an instrument into a working channel of the medical device,'}contacting the target site with the biocompatible patch; androtating the instrument relative to the working channel to apply the biocompatible patch to the target site and release the biocompatible patch from the instrument.22. The method of claim 21 , further comprising moving the instrument to a position outside of the working channel.23. The method of claim 21 , further comprising securing the biocompatible patch to the target site.24. The method of claim 21 , wherein the instrument is rotated about a longitudinal axis of the instrument.25. The method of claim 21 , wherein applying the biocompatible patch comprises unwinding the biocompatible patch from the instrument onto the target site.26. The method of claim 21 , wherein the instrument is coupled to a mechanism configured to rotate the instrument relative to the working ...

大鲵分泌物生物膜及其制备方法和应用

本发明公开了一种大鲵分泌物生物膜及其制备方法和应用，先将大鲵分泌物溶解在含氟极性溶剂中，得到大鲵分泌物溶液，然后将大鲵分泌物溶液冻干成膜或真空干燥成膜，得到大鲵分泌物生物膜。发明人经过大量的探索研究，预料不到地发现，大鲵分泌物在含氟极性溶剂中具有较高的溶解度。这种制备方法不破坏大鲵分泌物的原有结构，形成的大鲵分泌物生物膜保留了大鲵分泌物较好的粘合性、生物相容性等优点，且该大鲵分泌物生物膜质地均匀、韧性和强度较好，能够作为止血膜、组织粘合膜或绷带等对创面进行覆盖或包裹，具有广阔的应用前景。

一种医用黏合剂

一种医用黏合剂，此医用黏合剂中含有未经改性的大鲵皮肤粘液成分，具备易于生产、完全降解，高粘附性和延展性、有效封闭伤口，以及促进伤口愈合等性能，适合用于手术创面和伤口处的皮肤和皮下组织黏合，尤其对涉及皮下脂肪组织的皮肤封闭较传统市售黏合剂具有更好的黏附效果。

大鲵分泌物生物膜及其制备方法和应用

本发明公开了一种大鲵分泌物生物膜及其制备方法和应用，先将大鲵分泌物溶解在含氟极性溶剂中，得到大鲵分泌物溶液，然后将大鲵分泌物溶液冻干成膜或真空干燥成膜，得到大鲵分泌物生物膜。发明人经过大量的探索研究，预料不到地发现，大鲵分泌物在含氟极性溶剂中具有较高的溶解度。这种制备方法不破坏大鲵分泌物的原有结构，形成的大鲵分泌物生物膜保留了大鲵分泌物较好的粘合性、生物相容性等优点，且该大鲵分泌物生物膜质地均匀、韧性和强度较好，能够作为止血膜、组织粘合膜或绷带等对创面进行覆盖或包裹，具有广阔的应用前景。

使用磷酸钙组合的骨接合剂的脊椎骨最小侵入性治疗(mitv)

本发明提供了一种生物相容、可注入、自固化、内粘性、骨键合和重塑的磷酸钙复合材料，及其用于修复如椎体成形术增强和椎体后凸成形术中的缺陷骨头的方法，如用于椎体成形术增强和椎体后凸成形术的方法。

Medical bio-fiber styptic powder material and preparation method thereof

本发明涉及生物医药止血材料，具体地涉及一种医用生物纤维止血粉材料及其制备方法，它由微孔淀粉、马勃孢子粉构成；微孔淀粉具有分子筛的作用，可快速吸收血液中的水分，形成“即时凝胶”，机械性封堵血管破口；马勃孢子粉储存有大量微多孔纤维，可迅速吸收血液中的水分，可机械性封堵血管破口及毛细血管渗血，微孔淀粉、马勃孢子粉共同形成物理屏障，可隔离伤口，起到防粘连和即时止血的作用。本发明用于各种创伤和新鲜组织创面渗血、小血管出血及出血区的止血，预防粘连。

Giant salamander secretion hydrogel and its preparation method and application

本发明公开了一种大鲵分泌物水凝胶及其制备方法和应用，大鲵分泌物水凝胶的原料包括大鲵分泌物、乙酸或乙酸溶液、藻酸盐以及溶剂。乙酸小分子能够打破了大鲵分泌物蛋白质链间/链内离子络合和氢键，当与藻酸盐混合时，来自蛋白质链的胺基和藻酸盐的羧酸基团的离子络合的交联网络在短时间内形成，从而得到在水中依然具有良好粘附性能的大鲵分泌物水凝胶。上述大鲵分泌物水凝胶还具有良好的自愈合能力，可广泛应用于生物粘合剂以及制备治疗创伤的药物中。

Bone cement and use method thereof

包含丙烯酸类聚合物混合物的骨水泥，由于丙烯酸类珠的分子量和/或尺寸的分布，所述骨水泥被配制为在较长的窗口具有较高的粘度。

INJECTABLE BONE REPLACEMENT MATERIAL CONTAINING BONE CEMENT AND OIL

Biologically absorbable implant material, and method for its preparation

Hemostatic device

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

Tissue-derived extracelluar matrix derivatives modified with phenol derivatives for fabrication of artificial tissue

본 발명은 인공 조직 제작을 위한 페놀 유도체로 수식된 조직 유래 세포외기질 유도체에 관한 것으로, 본 발명의 하이드로젤용 조성물 및 이로부터 제조된 하이드로젤은 지혈, 혈액 응고 촉진, 세포 이식, 약물 전달, 세포 분화 촉진 등 다양한 효과를 나타내어 단일 또는 복합 용도로서 활용할 수 있다. 나아가, 본 발명은 세포 독성이 거의 없으면서도 생분해가 가능하여 생체 적합성이 매우 우수하여 활용 가능성이 매우 높다. 또한, 본 발명의 하이드로젤의 세포 배양능 및 접착성을 통해 단일 또는 복수 종류의 세포를 포함하는 조직 구조체를 형성하여 체내 미세환경을 더욱 잘 묘사할 수 있다.

Methods and compositions for achieving hemostasis and stable blood clot formation

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

Minimally Invasive Treatment of Vertebra(MITV) Using a Calcium Phosphate Combination Bone Cement

본 발명의 특징은 생적합성, 주입형, 자가경화성, 응집성, 골결합성 및 리모델링 칼슘 포스페이트 복합체 물질 및 그의 결함성 골의 회복방법, 예컨대 척추성형 거상술 및 척추후굴풍선복원술에서의 용도이다.

Thrombin isolated from blood and blood fractions

Methods, apparatus, and compositions related to generating and using thrombin. Methods include preparing a solution comprising thrombin by precipitating fibrinogen from a liquid comprising whole blood or a blood fraction. Precipitated fibrinogen is removed from the liquid to form a post-precipitation liquid that is incubated with calcium and a plurality of beads to form a clot. A solution comprising thrombin is separated from the clot. Thrombin prepared thereby can be used as a tissue sealant and in methods of applying a tissue sealant to subject, including application of an autologous tissue sealant.

Method of producing agent for stimulating connections between parts of living mineralized tissue

FIELD: medicine. SUBSTANCE: composition is prepared by regenerating mineralized tissue on at least one of said tissue parts. This composition contains protein fraction of dental enamel predecessor. EFFECT: improves desired product quality. 2 dwg, 4 tbl 516300с ПЧ Го РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (19) (51) МПК ВИ” 2008 915 ' 13) Сл А 61 К 37/02// А 61 К 35/32 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 4831270/14, 17.09.1990 (30) Приоритет: 3Е/17.03.88/8800980 (30) Приоритет: 17.03.1988 ЗЕ 88 8800980 (46) Дата публикации: 15.03.1994 (71) Заявитель: Биора АБ ($Е) (72) Изобретатель: Ларс Хаммарстрем[3Е], Лейф Бломлеф[ЗЕ], Свен Линдско[3ЗЕ] (73) Патентообладатель: Биовентурес Н.В. (МЕ) (54) СПОСОБ ПОЛУЧЕНИЯ СРЕДСТВА ДЛЯ СТИМУЛИРОВАНИЯ СОЕДИНЕНИЯ МЕЖДУ ЧАСТЯМИ ЖИВОЙ МИНЕРАЛИЗОВАННОЙ ТКАНИ (57) Реферат: Использование медицина. Цель - расширение спектра средств, обладающих способностью стимулировать соединение между частями живой минерализованной ткани. Сущность изобретения получают состав для применения с целью стимулирования соединения между двумя частями минерализованной ткани путем регенерирования минерализованной ткани, по меньшей мере на одной из частей, содержащий В качестве активной составляющей протеиновую фракцию из предшественника зубной эмали, так называемой эмаль-матки. 1 ил. ‚ 4 табл. 2008915 С1 КО 516300с ПЧ Го (19) 13) ВИ ”” 2008 915” С1 59° А 64 К 37/02// А 61 К 35/32 КУЗЗАМ АСЕМСУ ГОК РАТЕМТ$ АМО ТКАОЕМАКК$ 12) АВЗТКАСТ ОЕ 1МУЕМТОМ (21), (22) Аррисаноп: 4831270/14, 17.09.1990 (71) АррИсапе: ВОВА АВ ($Е) (30) Рношу: 3Е/17.03.88/8800980 (72) пуепог. ЕАВЗ КНАММАБЗТВЕМ[$Е1, (30) Рпощу: 17.03.1988 ЗЕ 88 8800980 ГЕУЕ ВЕОМЕЕЕ[ЗЕ], ЗУЕМ ИМОЗКОС[$Е] (46) Рае оГ рибИсаНоп: 15.03.1994 (73) Ргорпег: ВОМЕМТУВЕЗ М.М. (МЕ) (54) МЕТНОО ОЕ РКОВУСМС АСЕМТ РОК ЭПИМУГАТМС СОММЕСТЮМ$ ВЕТМЕЕМ РАКТЗ ОЕ ИММС ММЕКАНУЕО Т1ЗЗУЕ (57) АБзасЕ: ТА сотрозШоп сощат$ ргфеп Тгасйоп НЕЕО: тесте. ЗУВЗТАМСЕ: сотрозШНоп оГ Чета! епате| ...

Anti-inflammation type rapid hemostasis medical adhesive material and preparation method thereof

本发明属于生物医用材料技术领域，具体涉及一种消炎型快速止血医用胶材料，并进一步公开其制备方法。本发明所述医用胶材料，以α‑氰基丙烯酸正丁酯和α‑氰基丙烯酸正辛酯作为混合医用胶基质，并通过以CO 2 超临界流体携带选定的离子液体和消炎活性成分对止血材料羧甲基壳聚糖进行溶胀改性的方式，不仅有效提高了羧甲基壳聚糖的止血性能，使得整个医用胶材料的止血性能大幅提升，实现快速止血，且使得所述医用胶具有了较好的抑菌性能，可适用于更多的临床场合。

Bone cement containing bone marrow

一种配置为引入到目标骨位置并允许其固化的骨水泥，其至少包括单体和一定量骨髓。所生成固化骨水泥包括至少一种所需机械特性，其可适应以匹配于目标骨的机械特性。所需机械特性可以是材料硬度(杨氏模量)或屈服强度。

Hydrogel bioscaffold and coating for bone and tooth repair

Hydrogel compositions that include an albumin/N-acetyl cysteine solution and an aqueous suspension of calcium salts or mixture of calcium and magnesium salts are described. Also described are methods of producing and using the hydrogel compositions as a support scaffold for mineralizing connective tissue replacement and repair.

Compositions for repair of cartilage and bone

A defect is provided in cartilage or bone, or both, to excize damaged or pathological tissue, and it is filled with an implant having capability for complete regeneration of the skeletal tissue as a chondrogenic or osteogenic phenotype. The implant comprises cells expressing a chondrocyte phenotype (80×10 6 cells/ml) embedded in a biocompatible matrix having about 20% serum, which provides a permissive environment for maturation and transformation of the implant to a fully integrated state with the surrounding tissue. A portion of the implant may comprise a bone segment or a bone substitute.